Page last updated: 2024-09-03

rasagiline and Idiopathic Parkinson Disease

rasagiline has been researched along with Idiopathic Parkinson Disease in 259 studies

Research

Studies (259)

TimeframeStudies, this research(%)All Research%
pre-19902 (0.77)18.7374
1990's2 (0.77)18.2507
2000's75 (28.96)29.6817
2010's150 (57.92)24.3611
2020's30 (11.58)2.80

Authors

AuthorsStudies
Bolognesi, ML; Cavalli, A; Melchiorre, C; Minarini, A; Recanatini, M; Rosini, M; Tumiatti, V1
Almos, T; Edmondson, DE; Massari, ME; Rojas, RJ; Scott, R1
Balogh, B; Chai, CL; Chua, YY; Deme, R; Gölöncsér, F; Ho, HK; Huleatt, PB; Khoo, ML; Liew, RS; Magyar, K; Mátyus, P; Sheela, DP; Sperlágh, B; Tan, TW1
Cai, P; Kong, L; Liu, Q; Wang, KDG; Wang, X; Wang, Z; Wu, J; Yang, X1
Bao, XQ; Gao, F; Li, L; Tao, D; Wang, L; Wang, Y; Yang, BB; Zhang, D1
Affini, A; Hagenow, S; Lutsenko, K; Reiner, D; Stark, H1
Danış, Ö; Elzien Alamin Ali, H; Odabaş, Z; Ozalp, L1
Archer, DB; Arpin, DJ; Burciu, RG; Chu, WT; Gao, H; Guttuso, T; Hess, CW; Lai, S; Malaty, IA; McFarland, NR; Mitchell, T; Okun, MS; Pasternak, O; Price, CC; Shukla, AW; Vaillancourt, DE; Wu, SS1
Arai, M; Furusawa, Y; Hanya, Y; Hattori, N; Kitagawa, T; Mochizuki, H; Nagai, M; Takahashi, R; Takeda, A1
Andrews, EB; Calingaert, B; Gordon, MF; Johannes, CB; Kaplan, S; Kaye, JA; Saltus, CW1
Brotchie, J; Friedman, H; Giladi, N; Hauser, RA; Litman, P; Oren, S; Poewe, W1
Beretta, J; Enzo, P; Mutti, C; Negrotti, A; Parrino, L; Pizzarotti, S; Rausa, F; Sarnataro, RB1
Chang, HY; Hong, CT; Kuan, YC; Li, YY1
Alborghetti, M; Bianchini, E; Galli, S; Pontieri, FE; Rinaldi, D; Sforza, M1
Bergmans, B; Bourgeois, P; Cras, P; De Klippel, N; Dethy, S; Franco, G; Garraux, G; Geens, K; Jacquerye, P; Jeanjean, A; Krygier, C; Supiot, F; Van der Linden, C1
Iguchi, Y; Kitagawa, T; Komatsu, T; Maku, T; Mimori, M; Mitsumura, H; Murakami, H; Okumura, M; Omoto, S; Ozawa, M; Sakai, K; Sato, T; Shiraishi, T; Takatsu, H; Umehara, T1
Bovenzi, R; Candelise, N; Ferri, A; Grillo, P; Mercuri, NB; Schirinzi, T; Simonetta, C; Valle, C; Zenuni, H1
Cai, G; Cai, H; Cui, Y; Feng, T; Lin, F; Su, D; Yan, R1
Cao, S; Chen, H; Hu, X; Liang, Z; Liu, Z; Mao, W; Shao, M; Song, Z; Su, W; Tang, B; Wei, W; Wu, Y; Zhang, K1
Gao, F; Gao, L; Miao, J; Yang, Y1
Diezma-Martín, A; García-Meléndez, DD; López-Ariztegui, N; Morales-Casado, MI1
Asano, H; Hatabu, A; Ikeda, K; Takagi, T; Tian, YS; Ueda, M1
Jiang, DQ; Jiang, LL; Li, MX; Wang, HK; Wang, Y1
Chung, YA; Heo, Y; Im, JJ; Jeong, H; Oh, JK; Park, JS; Song, IU1
Afonso, ND; Chapela, D; Correia, AD; Outeiro, TF; Sousa, S; van der Linde, HC; Vaz, RL; Willemsen, R1
Lv, C; Wang, M; Zhang, Q; Zhou, W; Zong, S1
Maruyama, W; Naoi, M; Shamoto-Nagai, M1
Alves, C; Gomes, P; Lázaro, DF; Outeiro, TF; Sharma, V; Silva, S; Vale, N1
Parambi, DGT1
Chappell, KB; Cutshall, BT; Sands, CW; Shah, SP1
Hattori, N; Nagai, M1
Del Rosario, MM; Jamora, RDG; Suratos, CTR1
Binde, CD; Gåsemyr, JI; Klemp, M; Natvig, B; Tvete, IF1
Fukuda, K; Hirano, M; Isono, C; Kusunoki, S; Samukawa, M1
Caminiti, G; Casali, M; D'Antoni, V; Grassini, P; Stocchi, F; Tomino, C; Torti, M; Vacca, L; Volterrani, M1
Matos, MJ1
Alborghetti, M; Bianchini, E; De Carolis, L; Della Gatta, F; Pontieri, FE; Rinaldi, D; Sforza, M1
Elmer, L; Friedman, H; Giladi, N; Hauser, RA; Kadosh, S; Kieburtz, K; Klepiskaya, OS; Kreitzman, DL; Leinonen, M; Lew, MF; Linvah, N; Litman, P; Olanow, CW; Russell, DS; The P B Study Group, F1
Capece, R; Hauser, RA; Hewitt, DJ; Ho, TW; Huyck, S; Lines, C; Michelson, D; Rascol, O; Sklar, P; Stocchi, F; Tzontcheva, A1
Canesi, M; Cereda, E; Cilia, R; Mariani, CB; Pezzoli, G; Tesei, S; Zecchinelli, AL1
Lang, AE; Levy, A1
Assogna, F; Pontieri, FE; Rinaldi, D; Sforza, M; Tagliente, S1
Cronin, A; Grealy, M1
Duan, D; Hua, H; Jiang, Y; Li, Y; Liu, W; Lu, X; Meng, Q; Mu, H; Sun, K; Wang, A; Wang, Y; Yan, X; Zhang, X1
Brandt, MD; Brown, S; Fauser, M; Graehlert, X; Löhle, M; Maaß, A; Ossig, C; Otto, K; Reichmann, H; Schrempf, W; Schwanebeck, U; Storch, A; Wienecke, M1
Magyar, K; Riederer, P; Szökő, É; Tábi, T; Vécsei, L1
Müller, T; Riederer, P1
Hattori, N; Kato, M; Mochizuki, H; Nagai, M; Nishimura, A; Takahashi, R; Takeda, A; Takeda, S1
Ahn, EH; Cao, X; Dhakal, S; Iuvone, PM; Kang, SS; Liu, X; Manfredsson, FP; Sandoval, IM; Ye, K; Zhang, Z1
Liguori, C; Mercuri, NB; Pierantozzi, M; Ruffini, R; Stefani, A1
Alborghetti, M; Nicoletti, F1
Hattori, N; Kitagawa, T; Mochizuki, H; Nagai, M; Nishimura, A; Takahashi, R; Takeda, A; Takeda, S2
Burke, WJ; Gillespie, KN; Hsu, FF; Kumar, VB; Lakshmi, VM1
Hattori, N; Mochizuki, H; Nagai, M; Nakaya, R; Nishimura, A; Takahashi, R; Takeda, A; Takeda, S1
Avila, A; Balagué-Marmaña, M; Caballol, N; Cardona, X; Gómez-Ruiz, I; Martín-Baranera, M; Planas-Ballvé, A1
Asano, AGC; Asano, NMJ; de Souza, PRE; Dos Santos, EUD; Duarte, EBC; Maia, MMD; Miranda, LMR1
Sheehan, J; Thorpe, M; Wilson, L1
Duval, F; Flabeau, O; Razafimahefa, J; Spampinato, U; Tison, F1
Chen, Y; Deng, L; Li, J; Qin, X; Sun, H; Tang, R; Yi, L; Zhang, C; Zhang, L; Zhang, Z; Zheng, J; Zhou, H1
Agúndez, JA; Alonso-Navarro, H; García-Martín, E; Jiménez-Jiménez, FJ1
Berkovich, E; Brundin, P; Fitzer-Attas, C; Fog, K; Hickery, M; Kallunki, P; Petit, GH1
de Groot, PW; Jordán, J; Mínguez-Mínguez, S; Solís-García del Pozo, J1
Antonini, A; Baroni, L; Belgrado, E; Borsato, C; Capozzoli, F; Gioulis, M; Marchini, C; Vitaliani, R; Volpe, D; Zambito Marsala, S1
Jordán, J; Mínguez-Mínguez, S; Solís-García Del Pozo, J1
Inaba-Hasegawa, K; Maruyama, W; Naoi, M1
Lew, MF1
Stocchi, F2
Ansorena, E; Blanco-Prieto, MJ; Garbayo, E1
Elmer, LW1
Jost, WH1
Hernández-Vara, J; Salvado, M1
Galvez-Jimenez, N; Kurako, K; Reyes, D1
Fauser, M; Haehner, A; Hummel, T; Klingelhöfer, L; Reichmann, H; Storch, A; Wolz, M1
Bartl, J; Gerlach, M; Grünblatt, E; Müller, T; Riederer, P1
Camacho-Ordoñez, A; Cervantes-Arriaga, A; González-Latapi, P; Martínez-Ramírez, D; Rodríguez-Violante, M; Velázquez-Osuna, S1
Kulisevsky, J; Pagonabarraga, J2
Mendzelevski, B; Rabinovich-Guilatt, L; Spiegelstein, O; Sprenger, CR1
Berkovich, E; Eyal, E; Jankovic, J; Tolosa, E1
Cesaro, P; Defebvre, L1
Cosentino, G; D'Amelio, M; Fierro, B; Mastrilli, S; Realmuto, S; Savettieri, G; Valentino, F1
Ali, A; Ali, J; Baboota, S; Fazil, M; Hasan, Q; Md, S; Mittal, D1
Kozak, HH; Uca, AU1
Bernardi, G; Brusa, L; Finazzi Agro', E; Iani, C; Musco, S; Pierantozzi, M; Stanzione, P; Stefani, A1
Miklya, I1
Choudhry, A; Eyal, E; Hauser, RA; Isaacson, S; Silver, D1
Marconi, S; Zwingers, T1
Bertotti, G; Boveri, N; Comi, C; Frazzitta, G; Ghilardi, MF; Maestri, R; Perini, M; Pezzoli, G; Riboldazzi, G; Turla, M; Uccellini, D1
Müller, T1
Chen, JJ; Conner, J; Mathena, J; Panisset, M; Rhyee, SH1
McCormack, PL1
Cai, B; Cai, JP; Chen, WJ; Lin, Y; Wang, N1
Eyal, E; Smith, KM; Weintraub, D1
Hauser, RA; Lang, A; Poewe, W1
Hanagasi, HA1
Abbruzzese, G; Antonini, A; Barone, P; Bonuccelli, U; Cossu, G; Lopiano, L; Meco, G; Morgante, L; Onofrj, M; Pezzoli, G; Santangelo, G; Stanzione, P; Tinazzi, M1
Habersack, A; Haehner, A; Hummel, T; Reichmann, H; Storch, A; Wienecke, M1
Fossati, C; Stocchi, F; Torti, M1
Gaillon, G; Le Goff, F; Lefaucheur, R; Maltête, D; Triquenot-Bagan, A1
Buda, S; Degli Esposti, L; Nobili, F; Piccinni, C; Sangiorgi, D1
Boger, HA; Cantwell, K; Granholm, AC; Hinson, VK; Ledreux, A1
Fernandez, HH; Gujrati, Y; Hennessy, C; Kluger, BM; Lim, TT; Malaty, IA; Nutter, B; Ojo, OO; Palacio, R; Patel, S; Rodriguez, RL; Swartz, C1
Abler, V; Eliaz, RE; Eyal, E; Hauser, RA1
Santimaleeworagun, W; Supasyndh, O; Suphanklang, J1
Choudhry, A; Davis, MD; Elm, JJ; Hauser, RA; Pagan, F; Weintraub, D1
Burciu, RG; Chung, JW; McFarland, NR; Ofori, E; Okun, MS; Pasternak, O; Shukla, P; Vaillancourt, DE1
Benetin, J; Cibulcik, F; Donath, V; Dvorak, M; Grofik, M; Kothaj, J; Kurca, E; Minar, M; Richter, D; Valkovic, P1
Abler, V; Berkovich, E; Collinson, S; Eliaz, RE; Eyal, E; Fitzer-Attas, C; Freeman, N; Grossman, I; Hayden, MR; Kennedy, JL; Knight, J; Lang, AE; Levy, J; Masellis, M; Tampakeras, M; Tchelet, A; Tiwari, A1
Csóka, M; Domján, G; Kellős, É; Molnár, S1
Fyfe, I1
Katunina, EA; Sotnikova, NN; Titova, NV1
Cerdán, DM; Duarte, J; Fernández, B; Simonet, C1
Abler, V; Fitzer-Attas, CJ; Hauser, RA; Olanow, CW; Rascol, O; Sidi, Y; Stocchi, F1
Jog, M; Rahimi, F; Roberts, AC1
Bélanger, M; Chouinard, S; Coffin, D; Lehoux, G; Panisset, M; Stril, JL1
Frakey, LL; Friedman, JH1
Desbordes, M; Gaillon, G; Guillaume, M; Hébant, B; Lefaucheur, R; Maltête, D1
Alawadi, F; Bashier, A; Hussain, AA; Ibrahim, FA; Rashid, F1
Chang, Y; Lei, K; Li, D; Liu, SY; Wang, LB1
Grünblatt, E; Müller, T; Riederer, P1
Salzman, P; Schwid, SR; White, WB1
Jost, WH; Klasser, M; Reichmann, H1
Eyal, E; Hauser, RA; Jankovic, J; Lang, A; Langston, W; Melamed, E; Olanow, CW; Poewe, W; Rascol, O; Stocchi, F; Tolosa, E1
Bertoni, JM; Elmer, LW1
Bats, JW; Brüning, J; Schmidt, MU1
Levin, OS1
Isaacson, SH1
Fitzer-Attas, CJ; Hauser, RA; Hurtig, HI; Lew, MF; Ondo, WG; Wojcieszek, J1
Olanow, CW; Schapira, AH1
Azulay, T; Brooks, DJ; Giladi, N; Melamed, E; Oertel, W; Poewe, WH; Rascol, O; Stocchi, F; Tal, J; Tolosa, E1
Brotchie, J; Fitzer-Attas, C1
Klivényi, P; Rákóczi, K; Vécsei, L1
Lewitt, PA2
Amit, T; Drigues, N; Sagi, Y; Weinreb, O; Youdim, MB1
Armand, C; Cochran, J; François, C; Haycox, A; Murteira, S1
Chuang, RS; Lang, AE1
Feigin, PD; Hauser, R; Jankovic, J; Lang, A; Langston, W; Melamed, E; Olanow, CW; Poewe, W; Rascol, O; Stocchi, F; Tolosa, E1
Burke, WJ; Lewitt, PA1
Amit, T; Bar-Am, O; Weinreb, O; Youdim, MB2
Reichmann, H2
Youdim, MB2
Schwarzschild, MA2
Büttner, T; Csoti, I; Kassubek, J; Reichmann, H; Riederer, P; Schulz, JB; Wüllner, U1
Ferreira, JJ; Sampaio, C1
Jost, WH; Reichmann, H1
Chen, JJ1
Olanow, CW; Rascol, O1
Ahlskog, JE; Uitti, RJ2
Adar, L; Goren, T; Sasson, N; Weiss, YM1
Fitzer-Attas, CJ; Goren, T; Hauser, RA; Hurtig, HI; Lew, MF; Ondo, WG; Wojcieszek, J1
Bortan, E; Leegwater-Kim, J1
Bozi, M; Christodoulou, C; Douzenis, A; Gasparinatos, G; Stamboulis, E; Stefanis, C; Stefanis, L; Stefanis, N1
Andronis, CA; Deftereos, SN1
Vanacore, N1
Korczyn, AD; Vakhapova, V1
Williams, R1
Armand, C; Groenendaal, H; Tarrants, ML1
Bloem, BR; Boon, AJ; van Laar, T1
Montgomery, EB1
Knudsen Gerber, DS1
Janszky, J; Kovacs, N; Nagy, F1
Barker, RA; Evans, JR1
Keller, D1
Fernandes, C; Kessel, B; Reddy, P1
Boĭko, AN; Ivanov, AK; Levin, OS1
Auinger, P; Hauser, RA1
Perez-Lloret, S; Rascol, O1
Eyal, E; Fitzer-Attas, CJ; Hauser, R; Jankovic, J; Lang, A; Langston, JW; Melamed, E; Olanow, CW; Poewe, W; Rascol, O; Stocchi, F; Tolosa, E; Weiss, YM1
Cakmur, R; Emre, M; Feyzioglu, A; Gunal, DI; Gurvit, H; Hanagasi, HA; Horozoglu, H; Sahin, HA; Tuncer, N; Unsalan, P; Yener, GG1
Chen, JJ; Wilkinson, JR1
Buck, PO; Silver, DE1
Stern, MB; Tolosa, E1
Rabey, JM; Stocchi, F1
Rascol, O3
Bel'gusheva, ME; Fedorova, NV; Tekaeva, FK1
Jenner, P; Langston, JW1
Amit, T; Mandel, SA; Riederer, P; Weinreb, O; Youdim, MB1
Chahine, LM; Stern, MB1
Conner, JB; Griffith, A; Salzman, PM; Seeberger, LC; Silver, D; Wilson, RE1
Amboni, M; Barone, P; Bombieri, F; Di Matteo, A; Fasano, A; Ferigo, L; Santangelo, G; Squintani, G; Tinazzi, M; Vitale, C1
Christine, CW; Marks, WJ; Ostrem, JL1
Tarrants, ML; Zagmutt, FJ1
Hoy, SM; Keating, GM1
Alvarez, MV; Grogan, PM1
Lee, AD; Strowd, LC; Yosipovitch, G1
Belavic, J1
Hoy, SM; Keating, GM; Lyseng-Williamson, KA1
Barcia, E; Fernández, M; Fernández-Carballido, A; Garcia, L; Negro, S; Slowing, K1
García-Ruiz, PJ; Luquin, MR1
Blin, O; Lancrenon, S; Pitel, S; Viallet, F1
Olanow, CW2
Dimpfel, W; Hoffmann, JA; Müller, T; Oehlwein, C1
Pagonabarraga, J; Rodríguez-Oroz, MC1
Barone, P; Errico, D; Erro, R; Improta, I; Manganelli, F; Moccia, M; Santangelo, G; Vitale, C1
Blindauer, K; Kieburtz, K; McDermott, M; Plumb, S; Shoulson, I; Siderowf, A1
Amit, T; Bar-Am, O; Weinstock, M; Yogev-Falach, M; Youdim, MB1
Lazarovici, P; Lecht, S; Tabakman, R1
Friedman, J; Hauser, RA; LeWitt, PA; Marek, KL; Olanow, CW; Stern, MB; Tarsy, D1
Jenner, P1
Fridkin, M; Youdim, MB; Zheng, H1
Ludin, HP1
Goetz, CG1
Plosker, GL; Siddiqui, MA1
Goetz, CG; Poewe, W; Rascol, O; Sampaio, C1
Jankovic, J; Olanow, CW1
Amit, T; Mandel, S; Weinreb, O; Youdim, MB1
Konitsiotis, S1
Blandini, F1
Chen, JJ; Swope, DM1
Oberpichler-Schwenk, H1
Shults, CW1
Bate, G; Kirkpatrick, P; Schapira, A1
Bhat, V; Weiner, WJ1
Miletzki, A1
Schapira, AH2
Burgut, FT; Henchcliffe, C; Schumacher, HC1
Bakhle, YS; Youdim, MB1
Biglan, KM; Blindauer, K; Eberly, S; Fahn, S; Goren, T; Kieburtz, K; Oakes, D; Plumb, S; Schwid, S; Shoulson, I; Siderowf, A; Stern, M1
Sharma, JC1
Cochran, JM; Eckert, L; Hudry, J; Keränen, T; Rinne, JO1
Chen, JJ; Ly, AV1
Eberly, SW; Goetz, CG; Oakes, D; Schwid, SR; Shoulson, I1
Siderowf, A; Stern, M1
Blindauer, K; Eberly, S; Elmer, L; Fahn, S; Goetz, C; Kieburtz, K; Oakes, D; Oren, S; Prisco, UL; Salzman, P; Schwid, S; Shoulson, I; Stern, M1
Blindauer, K; deMarcaida, JA; Fahn, S; Kieburtz, K; Schwid, SR; Shoulson, I; Stern, M; White, WB1
Uitti, RJ; Wszolek, ZK1
Guay, DR1
Keating, GM; Oldfield, V; Perry, CM1
Chen, JJ; Fernandez, HH2
Hermanowicz, N1
Akao, Y; Maruyama, W; Naoi, M; Shamoto-Nagai, M; Yamaoka, Y; Yi, H1
Chen, JJ; Dashtipour, K; Swope, DM1
Freeman, JW; Matos, E; Simmons, M1
Linazasoro, G1
Bankiewicz, KS; Finberg, JP; Goldstein, DS; Kopin, IJ; Wang, J1
Maruyama, W; Naoi, M1
Bradford, HF; Goggi, J; Jauniaux, E; Riaz, SS; Stern, GM; Theofilopoulos, S1
Akao, Y; Davis, BA; Maruyama, W; Naoi, M; Youdim, MB1
Kupsch, A1
Riederer, P; Youdim, MB1
Finberg, JP; Youdim, MB1

Reviews

83 review(s) available for rasagiline and Idiopathic Parkinson Disease

ArticleYear
Multi-target-directed ligands to combat neurodegenerative diseases.
    Journal of medicinal chemistry, 2008, Feb-14, Volume: 51, Issue:3

    Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Binding Sites; Calcium Channel Blockers; Chelating Agents; Cholinesterase Inhibitors; Humans; Huntington Disease; Ligands; Multiple Sclerosis; Neurodegenerative Diseases; Neurofibrillary Tangles; Neurotransmitter Agents; Parkinson Disease; Plaque, Amyloid

2008
P2B001 (Extended Release Pramipexole and Rasagiline): A New Treatment Option in Development for Parkinson's Disease.
    Advances in therapy, 2022, Volume: 39, Issue:5

    Topics: Humans; Indans; Levodopa; Parkinson Disease; Pramipexole

2022
Efficacy of rasagiline monotherapy for early Parkinson disease: A systematic review and meta-analysis of randomized controlled trials.
    Journal of psychopharmacology (Oxford, England), 2022, Volume: 36, Issue:6

    Topics: Databases, Factual; Humans; Indans; Parkinson Disease; Randomized Controlled Trials as Topic

2022
Monoamine-oxidase Type B Inhibitors and Cognitive Functions in Parkinson's Disease: Beyond the Primary Mechanism of Action.
    Current neuropharmacology, 2023, Volume: 21, Issue:5

    Topics: Antiparkinson Agents; Cognition; Dopamine; Humans; Indans; Levodopa; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease; Quality of Life; Selegiline

2023
Comparative efficacy and safety of monoamine oxidase type B inhibitors plus channel blockers and monoamine oxidase type B inhibitors as adjuvant therapy to levodopa in the treatment of Parkinson's disease: a network meta-analysis of randomized controlled
    European journal of neurology, 2023, Volume: 30, Issue:4

    Topics: Antiparkinson Agents; Bayes Theorem; Humans; Indans; Levodopa; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Network Meta-Analysis; Parkinson Disease; Randomized Controlled Trials as Topic; Selegiline; Zonisamide

2023
Rasagiline combined with levodopa therapy versus levodopa monotherapy for patients with Parkinson's disease: a systematic review.
    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2020, Volume: 41, Issue:1

    Topics: Antiparkinson Agents; Drug Therapy, Combination; Humans; Indans; Levodopa; Neuroprotective Agents; Parkinson Disease; Randomized Controlled Trials as Topic

2020
Rasagiline and selegiline modulate mitochondrial homeostasis, intervene apoptosis system and mitigate α-synuclein cytotoxicity in disease-modifying therapy for Parkinson's disease.
    Journal of neural transmission (Vienna, Austria : 1996), 2020, Volume: 127, Issue:2

    Topics: alpha-Synuclein; Animals; Apoptosis; Homeostasis; Humans; Indans; Mitochondria; Monoamine Oxidase Inhibitors; Parkinson Disease; Selegiline

2020
Treatment of Parkinson's Disease by MAO-B Inhibitors, New Therapies and Future Challenges - A Mini-Review.
    Combinatorial chemistry & high throughput screening, 2020, Volume: 23, Issue:9

    Topics: Alanine; Benzylamines; Biomarkers; Clinical Trials as Topic; Functional Neuroimaging; Genetic Therapy; Humans; Indans; Levodopa; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Nanoparticles; Neuroprotective Agents; Parkinson Disease; Selegiline; Transplantation

2020
[Pharmacological properties and clinical efficacy of rasagiline mesylate (Azilect
    Nihon yakurigaku zasshi. Folia pharmacologica Japonica, 2020, Volume: 155, Issue:3

    Topics: Antiparkinson Agents; Clinical Trials as Topic; Humans; Indans; Japan; Monoamine Oxidase Inhibitors; Parkinson Disease; Treatment Outcome

2020
Comparative effectiveness of dopamine agonists and monoamine oxidase type-B inhibitors for Parkinson's disease: a multiple treatment comparison meta-analysis.
    European journal of clinical pharmacology, 2020, Volume: 76, Issue:12

    Topics: Dopamine Agonists; Drug Therapy, Combination; Humans; Indans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Randomized Controlled Trials as Topic; Selegiline; Treatment Outcome

2020
Multitarget therapeutic approaches for Alzheimer's and Parkinson's diseases: an opportunity or an illusion?
    Future medicinal chemistry, 2021, Volume: 13, Issue:15

    Topics: Alzheimer Disease; Donepezil; Drug Synergism; Humans; Indans; Neuroprotective Agents; Parkinson Disease; Protein Aggregates; Small Molecule Libraries

2021
Pharmacological aspects of the neuroprotective effects of irreversible MAO-B inhibitors, selegiline and rasagiline, in Parkinson's disease.
    Journal of neural transmission (Vienna, Austria : 1996), 2018, Volume: 125, Issue:11

    Topics: Humans; Indans; Monoamine Oxidase Inhibitors; Neuroprotection; Neuroprotective Agents; Parkinson Disease; Selegiline

2018
Monoamine oxidase-B inhibitors in the treatment of Parkinson's disease: clinical-pharmacological aspects.
    Journal of neural transmission (Vienna, Austria : 1996), 2018, Volume: 125, Issue:11

    Topics: Humans; Indans; Monoamine Oxidase Inhibitors; Neurons; Parkinson Disease; Selegiline

2018
Different Generations of Type-B Monoamine Oxidase Inhibitors in Parkinson's Disease: From Bench to Bedside.
    Current neuropharmacology, 2019, Volume: 17, Issue:9

    Topics: Alanine; Antiparkinson Agents; Benzylamines; Dopamine Agents; Humans; Indans; Levodopa; Male; Monoamine Oxidase Inhibitors; Parkinson Disease; Selegiline

2019
Anti-Parkinson's disease drugs and pharmacogenetic considerations.
    Expert opinion on drug metabolism & toxicology, 2013, Volume: 9, Issue:7

    Topics: Aryl Hydrocarbon Hydroxylases; Benzothiazoles; Benztropine; Bromocriptine; Cabergoline; Catechols; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Ergolines; Genetic Markers; Humans; Indans; Indoles; Levodopa; Lisuride; Nitriles; Parkinson Disease; Pergolide; Pharmacogenetics; Pramipexole; Receptors, Dopamine D2; Receptors, Dopamine D3; Reproducibility of Results; Selegiline

2013
Rasagiline meta-analysis: a spotlight on clinical safety and adverse events when treating Parkinson's disease.
    Expert opinion on drug safety, 2013, Volume: 12, Issue:4

    Topics: Clinical Trials as Topic; Double-Blind Method; Humans; Indans; Monoamine Oxidase Inhibitors; Parkinson Disease

2013
Rasagiline in Parkinson's disease: a review based on meta-analysis of clinical data.
    Pharmacological research, 2013, Volume: 74

    Topics: Antiparkinson Agents; Humans; Indans; Parkinson Disease

2013
Revelation in the neuroprotective functions of rasagiline and selegiline: the induction of distinct genes by different mechanisms.
    Expert review of neurotherapeutics, 2013, Volume: 13, Issue:6

    Topics: Animals; Apoptosis; Gene Expression; Genes, bcl-2; Humans; Indans; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Nerve Growth Factors; Neuroprotective Agents; Parkinson Disease; Selegiline

2013
Drug development in Parkinson's disease: from emerging molecules to innovative drug delivery systems.
    Maturitas, 2013, Volume: 76, Issue:3

    Topics: Animals; Blood-Brain Barrier; Dopamine; Drug Delivery Systems; Genetic Therapy; Glial Cell Line-Derived Neurotrophic Factor; Humans; Indans; Neuroprotective Agents; Parkinson Disease

2013
[Dopaminergic treatment in Parkinson's disease: what has each therapeutic family got to offer?].
    Revista de neurologia, 2014, Jan-01, Volume: 58, Issue:1

    Topics: Amantadine; Antiparkinson Agents; Cardiovascular Diseases; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Clinical Trials as Topic; Dopamine Agonists; Drug Interactions; Drug Therapy, Combination; Enzyme Inhibitors; Food-Drug Interactions; Humans; Indans; Indoles; Levodopa; Mental Disorders; Monoamine Oxidase Inhibitors; Multicenter Studies as Topic; Parkinson Disease; Serotonin Syndrome; Treatment Outcome

2014
[Drug treatment of early-stage (de novo and "honeymoon") Parkinson disease].
    Revue neurologique, 2014, Volume: 170, Issue:4

    Topics: Aged; Antidepressive Agents; Antiparkinson Agents; Female; Humans; Indans; Male; Middle Aged; Neuroprotective Agents; Parkinson Disease

2014
Comparative efficacy of selegiline versus rasagiline in the treatment of early Parkinson's disease.
    European review for medical and pharmacological sciences, 2014, Volume: 18, Issue:13

    Topics: Antiparkinson Agents; Humans; Indans; Monoamine Oxidase Inhibitors; Parkinson Disease; Randomized Controlled Trials as Topic; Selegiline; Treatment Outcome

2014
Pharmacokinetic/pharmacodynamic evaluation of rasagiline mesylate for Parkinson's disease.
    Expert opinion on drug metabolism & toxicology, 2014, Volume: 10, Issue:10

    Topics: Animals; Antiparkinson Agents; Catechols; Disease Progression; Humans; Indans; Monoamine Oxidase Inhibitors; Nitriles; Oxidative Stress; Parkinson Disease; Selegiline

2014
Rasagiline: a review of its use in the treatment of idiopathic Parkinson's disease.
    CNS drugs, 2014, Volume: 28, Issue:11

    Topics: Administration, Oral; Clinical Trials as Topic; Drug Administration Schedule; Drug Interactions; Humans; Indans; Monoamine Oxidase Inhibitors; Parkinson Disease; Treatment Outcome

2014
Safety and efficacy of rasagiline in addition to levodopa for the treatment of idiopathic Parkinson's disease: a meta-analysis of randomised controlled trials.
    European neurology, 2015, Volume: 73, Issue:1-2

    Topics: Antiparkinson Agents; Drug Therapy, Combination; Female; Humans; Indans; Levodopa; Male; Neuroprotective Agents; Outcome Assessment, Health Care; Parkinson Disease; Quality of Life; Randomized Controlled Trials as Topic

2015
Rasagiline for the treatment of Parkinson's disease: an update.
    Expert opinion on pharmacotherapy, 2015, Volume: 16, Issue:14

    Topics: Antiparkinson Agents; Apoptosis; Clinical Trials as Topic; Cognition Disorders; Drug Therapy, Combination; Fatigue; Humans; Indans; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Parkinson Disease; Quality of Life

2015
Efficacy of rasagiline in early Parkinson's disease: a meta-analysis of data from the TEMPO and ADAGIO studies.
    The International journal of neuroscience, 2016, Volume: 126, Issue:10

    Topics: Clinical Trials, Phase III as Topic; Humans; Indans; Monoamine Oxidase Inhibitors; Outcome Assessment, Health Care; Parkinson Disease

2016
[Comorbid states in Parkinson's disease: an effect of MAO-B inhibitors].
    Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2016, Volume: 116, Issue:4

    Topics: Aged; Antiparkinson Agents; Comorbidity; Depression; Fatigue; Humans; Indans; Monoamine Oxidase Inhibitors; Parkinson Disease

2016
Efficacy of rasagiline for the treatment of Parkinson's disease: an updated meta-analysis.
    Annals of medicine, 2017, Volume: 49, Issue:5

    Topics: Aged; Drug Therapy, Combination; Female; Humans; Indans; Male; Middle Aged; Monoamine Oxidase Inhibitors; Parkinson Disease; Severity of Illness Index; Treatment Outcome

2017
The increasing role of monoamine oxidase type B inhibitors in Parkinson's disease therapy.
    Expert opinion on pharmacotherapy, 2008, Volume: 9, Issue:16

    Topics: Animals; Clinical Trials as Topic; Humans; Indans; Levodopa; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease

2008
[The use of a new MAO B inhibitor rasagiline in the treatment of motor fluctuations in Parkinson's disease].
    Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2008, Volume: 108, Issue:9

    Topics: Humans; Indans; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease

2008
Mechanisms compensating for dopamine loss in early Parkinson disease.
    Neurology, 2009, Feb-17, Volume: 72, Issue:7 Suppl

    Topics: Antiparkinson Agents; Corpus Striatum; Disease Progression; Dopamine; Globus Pallidus; Humans; Indans; Levodopa; Neural Pathways; Neurons; Parkinson Disease

2009
[Neuroprotection in Parkinson's disease and other neurodegenerative disorders: preclinical and clinical findings].
    Ideggyogyaszati szemle, 2009, Jan-30, Volume: 62, Issue:1-2

    Topics: Animals; Creatine; Dopamine Agonists; Glatiramer Acetate; Humans; Indans; Kynurenic Acid; Micronutrients; Nerve Degeneration; Neurodegenerative Diseases; Neuroprotective Agents; Oxidative Stress; Parkinson Disease; Peptides; Selegiline; Tocopherols; Ubiquinone

2009
MAO-B inhibitor know-how: back to the pharm.
    Neurology, 2009, Apr-14, Volume: 72, Issue:15

    Topics: Antiparkinson Agents; Humans; Indans; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease; Selegiline

2009
The neuroprotective mechanism of 1-(R)-aminoindan, the major metabolite of the anti-parkinsonian drug rasagiline.
    Journal of neurochemistry, 2010, Volume: 112, Issue:5

    Topics: Animals; Cytochrome P-450 Enzyme System; Humans; Indans; Models, Chemical; Neuroprotective Agents; Parkinson Disease; Proto-Oncogene Proteins c-bcl-6

2010
[Diagnosis and therapy of idiopathic Parkinson's disease].
    MMW Fortschritte der Medizin, 2006, May-15, Volume: Spec no. 2

    Topics: Adult; Aged; Apomorphine; Deep Brain Stimulation; Diagnosis, Differential; Dopamine Agonists; Humans; Indans; Levodopa; Mental Status Schedule; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Parkinson Disease

2006
[On the role of MAO B inhibitors and NMDA antagonists in the therapy of Parkinson's disease].
    Fortschritte der Neurologie-Psychiatrie, 2010, Volume: 78 Suppl 1

    Topics: Amantadine; Excitatory Amino Acid Antagonists; Humans; Indans; Memantine; Monoamine Oxidase; Monoamine Oxidase Inhibitors; N-Methylaspartate; Parkinson Disease; Piperidines; Selegiline

2010
Parkinson's disease: health-related quality of life, economic cost, and implications of early treatment.
    The American journal of managed care, 2010, Volume: 16 Suppl Implications

    Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Disease Progression; Early Diagnosis; Health Care Costs; Humans; Indans; Middle Aged; Parkinson Disease; Quality of Life

2010
Rasagiline, Parkinson neuroprotection, and delayed-start trials: still no satisfaction?
    Neurology, 2010, Apr-06, Volume: 74, Issue:14

    Topics: Activities of Daily Living; Disability Evaluation; Dose-Response Relationship, Drug; Evidence-Based Medicine; Humans; Indans; Neuroprotective Agents; Observer Variation; Outcome Assessment, Health Care; Parkinson Disease; Patient Satisfaction; Patient Selection; Randomized Controlled Trials as Topic; Reproducibility of Results; Research Design; Severity of Illness Index; Time Factors

2010
The role of rasagiline in the treatment of Parkinson's disease.
    Clinical interventions in aging, 2010, May-25, Volume: 5

    Topics: Aged; Drug Interactions; Humans; Indans; Monoamine Oxidase Inhibitors; Parkinson Disease; Randomized Controlled Trials as Topic; Treatment Outcome

2010
Rasagiline: a novel anti-Parkinsonian monoamine oxidase-B inhibitor with neuroprotective activity.
    Progress in neurobiology, 2010, Volume: 92, Issue:3

    Topics: Animals; Antiparkinson Agents; Cells, Cultured; Disease Models, Animal; Humans; Indans; Models, Molecular; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Nerve Growth Factors; Neuroprotective Agents; Parkinson Disease; Protein Structure, Quaternary; Selegiline

2010
[Rasagiline: effectiveness and protection in Parkinson's disease].
    Revista de neurologia, 2010, Nov-01, Volume: 51, Issue:9

    Topics: Humans; Indans; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Parkinson Disease; Treatment Outcome

2010
Selegiline and rasagiline: twins or distant cousins?
    The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists, 2011, Volume: 26, Issue:1

    Topics: Humans; Inactivation, Metabolic; Indans; Monoamine Oxidase Inhibitors; Parkinson Disease; Selegiline

2011
Defining meaningful outcome measures in trials of disease-modifying therapies in Parkinson's disease.
    Expert opinion on pharmacotherapy, 2011, Volume: 12, Issue:8

    Topics: Disease Progression; Endpoint Determination; Humans; Indans; Movement Disorders; Neuroprotective Agents; Parkinson Disease; Posture; Reflex, Abnormal; Research Design; Treatment Outcome

2011
Safety of rasagiline for the treatment of Parkinson's disease.
    Expert opinion on drug safety, 2011, Volume: 10, Issue:4

    Topics: Animals; Clinical Trials as Topic; Drug Interactions; Drug-Related Side Effects and Adverse Reactions; Food-Drug Interactions; Humans; Indans; Parkinson Disease; Serotonin Agents; Treatment Outcome

2011
The monoamine oxidase type B inhibitor rasagiline in the treatment of Parkinson disease: is tyramine a challenge?
    Journal of clinical pharmacology, 2012, Volume: 52, Issue:5

    Topics: Antiparkinson Agents; Brain; Dietary Proteins; Dose-Response Relationship, Drug; Food-Drug Interactions; Humans; Hypertension; Indans; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease; Patient Safety; Risk Assessment; Risk Factors; Treatment Outcome; Tyramine

2012
Determining the efficacy of rasagiline in reducing bradykinesia among Parkinson's disease patients: a review.
    The International journal of neuroscience, 2011, Volume: 121, Issue:9

    Topics: Databases, Factual; Humans; Hypokinesia; Indans; Neuroprotective Agents; Parkinson Disease

2011
Explaining ADAGIO: a critical review of the biological basis for the clinical effects of rasagiline.
    Movement disorders : official journal of the Movement Disorder Society, 2011, Volume: 26, Issue:13

    Topics: Animals; Cell Death; Clinical Trials as Topic; Humans; Indans; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neurons; Neuroprotective Agents; Parkinson Disease

2011
Neuroprotective profile of the multitarget drug rasagiline in Parkinson's disease.
    International review of neurobiology, 2011, Volume: 100

    Topics: Animals; Humans; Indans; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Parkinson Disease; Structure-Activity Relationship

2011
Rasagiline in Parkinson's disease.
    International review of neurobiology, 2011, Volume: 100

    Topics: Animals; Humans; Indans; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Parkinson Disease

2011
Indirect comparisons of adverse events and dropout rates in early Parkinson's disease trials of pramipexole, ropinirole, and rasagiline.
    The International journal of neuroscience, 2012, Volume: 122, Issue:7

    Topics: Antiparkinson Agents; Benzothiazoles; Cognition Disorders; Cross-Sectional Studies; Databases, Bibliographic; Fatigue; Female; Gastrointestinal Diseases; Humans; Indans; Indoles; Logistic Models; Male; Parkinson Disease; Patient Dropouts; Pramipexole; Sleep Wake Disorders; Treatment Outcome

2012
Rasagiline: a review of its use in the treatment of idiopathic Parkinson's disease.
    Drugs, 2012, Mar-26, Volume: 72, Issue:5

    Topics: Antiparkinson Agents; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Indans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease

2012
[Limits of conventional oral and transdermal medication in Parkinson's disease].
    Revista de neurologia, 2012, Volume: 55 Suppl 1

    Topics: Administration, Cutaneous; Administration, Oral; Antiparkinson Agents; Apomorphine; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Clinical Trials as Topic; Dopamine Agonists; Drug Therapy, Combination; Enzyme Inhibitors; Half-Life; Humans; Indans; Injections, Subcutaneous; Levodopa; Meta-Analysis as Topic; Multicenter Studies as Topic; Parkinson Disease

2012
[Rasagiline in monotherapy in patients with early stages of Parkinson's disease and in combined and adjunct therapy to levodopa with moderate and advanced stages].
    Revista de neurologia, 2013, Jan-01, Volume: 56, Issue:1

    Topics: Antiparkinson Agents; Attention; Clinical Trials as Topic; Cognition Disorders; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Therapy, Combination; Executive Function; Fatigue; Headache; Humans; Indans; Levodopa; Monoamine Oxidase Inhibitors; Motor Activity; Multicenter Studies as Topic; Nausea; Neuroprotective Agents; Parkinson Disease; Severity of Illness Index

2013
Preclinical evidence for neuroprotection with monoamine oxidase-B inhibitors in Parkinson's disease.
    Neurology, 2004, Oct-12, Volume: 63, Issue:7 Suppl 2

    Topics: Amphetamines; Animals; Antiparkinson Agents; Apoptosis; Clinical Trials as Topic; Drug Evaluation, Preclinical; Haplorhini; Humans; Inactivation, Metabolic; Indans; Mice; Mice, Transgenic; Models, Neurological; Monoamine Oxidase Inhibitors; Neurons; Neuroprotective Agents; Oxepins; Oxidative Stress; Pargyline; Parkinson Disease; Propylamines; Selegiline

2004
Clinical trials of neuroprotection for Parkinson's disease.
    Neurology, 2004, Oct-12, Volume: 63, Issue:7 Suppl 2

    Topics: Antiparkinson Agents; Clinical Trials as Topic; Creatine; Dopamine Agonists; Double-Blind Method; Humans; Indans; Minocycline; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Multicenter Studies as Topic; Nerve Tissue Proteins; Neuroprotective Agents; Oxepins; Parkinson Disease; Picolinic Acids; Randomized Controlled Trials as Topic; Riluzole; Selegiline; Ubiquinone

2004
[Are there innovations in the treatment of Parkinson's disease?].
    Praxis, 2004, Nov-03, Volume: 93, Issue:45

    Topics: Antiparkinson Agents; Cannabis; Cholinesterase Inhibitors; Controlled Clinical Trials as Topic; Dopamine Agonists; Heart Valve Diseases; Humans; Indans; Levodopa; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Parkinson Disease; Pergolide; Phenylcarbamates; Placebos; Rivastigmine; Time Factors

2004
Movement disorders: understanding clinical trials.
    The Lancet. Neurology, 2005, Volume: 4, Issue:1

    Topics: Antiparkinson Agents; Clinical Trials as Topic; Humans; Indans; Movement Disorders; Neuroprotective Agents; Parkinson Disease; Randomized Controlled Trials as Topic; Research Design; Tomography, Emission-Computed, Single-Photon

2005
Rasagiline.
    Drugs & aging, 2005, Volume: 22, Issue:1

    Topics: Biological Availability; Clinical Trials as Topic; Humans; Indans; Monoamine Oxidase Inhibitors; Parkinson Disease; Treatment Outcome

2005
Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004.
    Movement disorders : official journal of the Movement Disorder Society, 2005, Volume: 20, Issue:5

    Topics: Amantadine; Antiparkinson Agents; Apomorphine; Benzophenones; Benzothiazoles; Bromocriptine; Cabergoline; Catechol O-Methyltransferase Inhibitors; Deep Brain Stimulation; Dihydroergocryptine; Ergolines; Fetal Tissue Transplantation; Globus Pallidus; Humans; Indans; Indoles; Levodopa; Lisuride; Mesencephalon; Monoamine Oxidase Inhibitors; Neurosurgical Procedures; Nitrophenols; Parkinson Disease; Pergolide; Piribedil; Pramipexole; Selegiline; Thiazoles; Tolcapone

2005
Neuroprotective therapy in Parkinson's disease and motor complications: a search for a pathogenesis-targeted, disease-modifying strategy.
    Movement disorders : official journal of the Movement Disorder Society, 2005, Volume: 20 Suppl 11

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Antiparkinson Agents; Coenzymes; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Humans; Indans; Levodopa; Membrane Proteins; N-Methylaspartate; Neuroprotective Agents; Parkinson Disease; Prostaglandin-Endoperoxide Synthases; Ubiquinone; Vitamin E

2005
Mechanism of neuroprotective action of the anti-Parkinson drug rasagiline and its derivatives.
    Brain research. Brain research reviews, 2005, Volume: 48, Issue:2

    Topics: Amyloid beta-Peptides; Animals; Apoptosis; Brain Chemistry; Ferritins; Humans; Indans; Mitochondria; Models, Neurological; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Parkinson Disease; Protein Kinase C; Signal Transduction

2005
Novel pharmacological strategies for motor complications in Parkinson's disease.
    Expert opinion on investigational drugs, 2005, Volume: 14, Issue:4

    Topics: Administration, Cutaneous; Animals; Antiparkinson Agents; Brain; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Catechols; Clinical Trials as Topic; Dopamine Agonists; Drug Delivery Systems; Drug Therapy, Combination; Enzyme Inhibitors; Humans; Indans; Levodopa; Liposomes; Monoamine Oxidase Inhibitors; Motor Neurons; Movement Disorders; Nitriles; Parkinson Disease; Receptors, Glutamate; Signal Transduction

2005
Neuroprotection by rasagiline: a new therapeutic approach to Parkinson's disease?
    CNS drug reviews, 2005,Summer, Volume: 11, Issue:2

    Topics: Animals; Apoptosis; Humans; Indans; Models, Neurological; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Parkinson Disease

2005
Clinical pharmacology of rasagiline: a novel, second-generation propargylamine for the treatment of Parkinson disease.
    Journal of clinical pharmacology, 2005, Volume: 45, Issue:8

    Topics: Animals; Clinical Trials as Topic; Drug Interactions; Humans; Indans; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Parkinson Disease; Selegiline

2005
Parkinson's disease. Diagnosis and the initiation of therapy.
    Minerva medica, 2005, Volume: 96, Issue:3

    Topics: Antioxidants; Diagnosis, Differential; Dopamine Agonists; Humans; Hypokinesia; Indans; Levodopa; Muscle Rigidity; Nerve Degeneration; Neuroprotective Agents; Parkinson Disease; Parkinsonian Disorders; Selegiline; Tremor

2005
Rasagiline in the pharmacotherapy of Parkinson's disease--a review.
    Expert opinion on pharmacotherapy, 2005, Volume: 6, Issue:12

    Topics: Antiparkinson Agents; Humans; Indans; Parkinson Disease

2005
Present and future drug treatment for Parkinson's disease.
    Journal of neurology, neurosurgery, and psychiatry, 2005, Volume: 76, Issue:11

    Topics: Benzothiazoles; Corpus Striatum; Disease Progression; Dopamine Agonists; Drug Therapy, Combination; Humans; Indans; Indoles; Levodopa; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease; Pramipexole; Psychomotor Performance; Sexual Dysfunction, Physiological; Sleep Wake Disorders; Substantia Nigra; Thiazoles; Urinary Incontinence

2005
Recent advances in Parkinson's disease therapy: use of monoamine oxidase inhibitors.
    Expert review of neurotherapeutics, 2005, Volume: 5, Issue:6

    Topics: Antiparkinson Agents; Brain; Clinical Trials as Topic; Diet Therapy; Dopamine Agents; Drug Evaluation; Drug Interactions; Expert Testimony; Humans; Indans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Selegiline

2005
Monoamine oxidase: isoforms and inhibitors in Parkinson's disease and depressive illness.
    British journal of pharmacology, 2006, Volume: 147 Suppl 1

    Topics: Animals; Cholinesterase Inhibitors; Dementia; Depressive Disorder; History, 20th Century; History, 21st Century; Humans; Indans; Iron; Iron Deficiencies; Isoenzymes; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Parkinson Disease; Selegiline

2006
Rasagiline: defining the role of a novel therapy in the treatment of Parkinson's disease.
    International journal of clinical practice, 2006, Volume: 60, Issue:2

    Topics: Delayed-Action Preparations; Humans; Indans; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Parkinson Disease; Treatment Outcome

2006
Rasagiline: A second-generation monoamine oxidase type-B inhibitor for the treatment of Parkinson's disease.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2006, May-15, Volume: 63, Issue:10

    Topics: Clinical Trials as Topic; Drug Interactions; Humans; Indans; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Parkinson Disease

2006
Concerning neuroprotective therapy for Parkinson's disease.
    Journal of neural transmission. Supplementum, 2006, Issue:70

    Topics: Clinical Trials as Topic; Humans; Indans; Neuroprotective Agents; Parkinson Disease

2006
Rasagiline (Azilect) for Parkinson's disease.
    The Medical letter on drugs and therapeutics, 2006, Dec-04, Volume: 48, Issue:1249/1250

    Topics: Humans; Indans; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease

2006
The path from anti Parkinson drug selegiline and rasagiline to multifunctional neuroprotective anti Alzheimer drugs ladostigil and m30.
    Current Alzheimer research, 2006, Volume: 3, Issue:5

    Topics: Alzheimer Disease; Animals; Antiparkinson Agents; Humans; Hydroxyquinolines; Indans; Models, Biological; Neuroprotective Agents; Parkinson Disease; Selegiline

2006
Rasagiline (TVP-1012): a new selective monoamine oxidase inhibitor for Parkinson's disease.
    The American journal of geriatric pharmacotherapy, 2006, Volume: 4, Issue:4

    Topics: Alzheimer Disease; Animals; Antiparkinson Agents; Drug Interactions; Humans; Indans; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Parkinson Disease; Treatment Outcome

2006
The use of rasagiline in Parkinson's disease.
    Journal of neural transmission. Supplementum, 2006, Issue:71

    Topics: Animals; Humans; Indans; Neuroprotective Agents; Parkinson Disease

2006
Rasagiline: a review of its use in the management of Parkinson's disease.
    Drugs, 2007, Volume: 67, Issue:12

    Topics: Animals; Antiparkinson Agents; Drug Therapy, Combination; Humans; Indans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease

2007
Community and long-term care management of Parkinson's disease in the elderly: focus on monoamine oxidase type B inhibitors.
    Drugs & aging, 2007, Volume: 24, Issue:8

    Topics: Aged; Aging; Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Catechol O-Methyltransferase Inhibitors; Dopamine Agonists; Homes for the Aged; Humans; Indans; Levodopa; Monoamine Oxidase Inhibitors; Nursing Homes; Parkinson Disease; Selegiline

2007
Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease.
    Clinical therapeutics, 2007, Volume: 29, Issue:9

    Topics: Antiparkinson Agents; Drug Interactions; Drug Therapy, Combination; Food-Drug Interactions; Humans; Indans; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Parkinson Disease; Selegiline

2007
Monoamine oxidase-B inhibition in the treatment of Parkinson's disease.
    Pharmacotherapy, 2007, Volume: 27, Issue:12 Pt 2

    Topics: Alanine; Antiparkinson Agents; Benzylamines; Dopamine Agonists; Humans; Indans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Selegiline

2007
Parkinson disease: an incremental challenge.
    South Dakota medicine : the journal of the South Dakota State Medical Association, 2007, Volume: 60, Issue:12

    Topics: Catechols; Deep Brain Stimulation; Disease Progression; Humans; Indans; Nitriles; Parkinson Disease

2007
[Rasagiline in Parkinson's disease].
    Neurologia (Barcelona, Spain), 2008, Volume: 23, Issue:4

    Topics: Humans; Indans; Neuroprotective Agents; Parkinson Disease

2008

Trials

54 trial(s) available for rasagiline and Idiopathic Parkinson Disease

ArticleYear
Diffusion Magnetic Resonance Imaging Detects Progression in Parkinson's Disease: A Placebo-Controlled Trial of Rasagiline.
    Movement disorders : official journal of the Movement Disorder Society, 2022, Volume: 37, Issue:2

    Topics: Diffusion Magnetic Resonance Imaging; Disease Progression; Double-Blind Method; Humans; Indans; Parkinson Disease; Prospective Studies

2022
Effects of rasagiline on Parkinson's Disease Questionnaire (PDQ-39) emotional well-being domain in patients with Parkinson's disease: A post-hoc analysis of clinical trials in Japan.
    PloS one, 2022, Volume: 17, Issue:1

    Topics: Aged; Antiparkinson Agents; Emotions; Female; Humans; Indans; Japan; Male; Parkinson Disease; Quality of Life; Surveys and Questionnaires; Treatment Outcome

2022
Pharmacokinetics, Pharmacodynamics, and Safety of a Single Escalating Dose and Repeated Doses of Rasagiline Transdermal Patch in Healthy Chinese Subjects.
    Clinical pharmacology in drug development, 2020, Volume: 9, Issue:5

    Topics: Administration, Cutaneous; Administration, Oral; Adult; Asian People; Body Mass Index; Dose-Response Relationship, Drug; Healthy Volunteers; Humans; Indans; Male; Middle Aged; Monoamine Oxidase Inhibitors; Parkinson Disease; Safety; Transdermal Patch

2020
A randomized trial of a low-dose Rasagiline and Pramipexole combination (P2B001) in early Parkinson's disease.
    Movement disorders : official journal of the Movement Disorder Society, 2017, Volume: 32, Issue:5

    Topics: Aged; Antiparkinson Agents; Benzothiazoles; Delayed-Action Preparations; Double-Blind Method; Drug Combinations; Female; Humans; Indans; Israel; Male; Middle Aged; Neuroprotective Agents; Parkinson Disease; Pramipexole; Severity of Illness Index; Triethylenemelamine; United States

2017
Randomized trial of preladenant, given as monotherapy, in patients with early Parkinson disease.
    Neurology, 2017, Jun-06, Volume: 88, Issue:23

    Topics: Activities of Daily Living; Adenosine A2 Receptor Antagonists; Antiparkinson Agents; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Indans; Internationality; Male; Middle Aged; Motor Activity; Parkinson Disease; Pyrimidines; Severity of Illness Index; Treatment Failure; Triazoles

2017
Rasagiline improves polysomnographic sleep parameters in patients with Parkinson's disease: a double-blind, baseline-controlled trial.
    European journal of neurology, 2018, Volume: 25, Issue:4

    Topics: Aged; Aged, 80 and over; Double-Blind Method; Female; Humans; Indans; Male; Middle Aged; Neuroprotective Agents; Parkinson Disease; Polysomnography; Sleep; Sleep Wake Disorders; Treatment Outcome

2018
Efficacy and safety of adjunctive rasagiline in Japanese Parkinson's disease patients with wearing-off phenomena: A phase 2/3, randomized, double-blind, placebo-controlled, multicenter study.
    Parkinsonism & related disorders, 2018, Volume: 53

    Topics: Adult; Aged; Antiparkinson Agents; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Indans; Japan; Levodopa; Male; Middle Aged; Monoamine Oxidase Inhibitors; Outcome Assessment, Health Care; Parkinson Disease

2018
Rasagiline monotherapy in early Parkinson's disease: A phase 3, randomized study in Japan.
    Parkinsonism & related disorders, 2019, Volume: 60

    Topics: Adult; Aged; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Indans; Japan; Male; Middle Aged; Monoamine Oxidase Inhibitors; Nasopharyngitis; Outcome Assessment, Health Care; Parkinson Disease; Severity of Illness Index

2019
Long-term safety and efficacy of adjunctive rasagiline in levodopa-treated Japanese patients with Parkinson's disease.
    Journal of neural transmission (Vienna, Austria : 1996), 2019, Volume: 126, Issue:3

    Topics: Adult; Aged; Antiparkinson Agents; Drug Therapy, Combination; Female; Humans; Indans; Japan; Levodopa; Male; Middle Aged; Parkinson Disease; Time; Treatment Outcome

2019
Long-term, open-label, phase 3 study of rasagiline in Japanese patients with early Parkinson's disease.
    Journal of neural transmission (Vienna, Austria : 1996), 2019, Volume: 126, Issue:3

    Topics: Adult; Aged; Antiparkinson Agents; Female; Humans; Indans; Japan; Male; Middle Aged; Parkinson Disease; Time

2019
Efficacy and safety of rasagiline as an adjunct to levodopa treatment in Chinese patients with Parkinson's disease: a randomized, double-blind, parallel-controlled, multi-centre trial.
    The international journal of neuropsychopharmacology, 2013, Volume: 16, Issue:7

    Topics: Adult; Aged; Antiparkinson Agents; Asian People; Cognition Disorders; Disease Progression; Double-Blind Method; Female; Humans; Indans; Levodopa; Male; Middle Aged; Neuroprotective Agents; Parkinson Disease

2013
Rasagiline treatment effects on parkinsonian tremor.
    The International journal of neuroscience, 2013, Volume: 123, Issue:12

    Topics: Databases, Factual; Double-Blind Method; Female; Humans; Indans; Male; Neuroprotective Agents; Parkinson Disease; Treatment Outcome; Tremor

2013
Benefits of treatment with rasagiline for fatigue symptoms in patients with early Parkinson's disease.
    European journal of neurology, 2014, Volume: 21, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Disease Progression; Double-Blind Method; Fatigue; Female; Humans; Indans; Male; Middle Aged; Monoamine Oxidase Inhibitors; Parkinson Disease; Severity of Illness Index; Treatment Outcome

2014
Rasagiline adjunct therapy in patients with Parkinson's disease: post hoc analyses of the PRESTO and LARGO trials.
    Parkinsonism & related disorders, 2013, Volume: 19, Issue:11

    Topics: Aged; Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Indans; Male; Middle Aged; Monoamine Oxidase Inhibitors; Parkinson Disease; Treatment Outcome

2013
Effects of rasagiline on olfactory function in patients with Parkinson’s disease.
    Movement disorders : official journal of the Movement Disorder Society, 2013, Volume: 28, Issue:14

    Topics: Administration, Intranasal; Aged; Double-Blind Method; Electroencephalography; Evoked Potentials; Female; Humans; Indans; Male; Middle Aged; Neuroprotective Agents; Olfaction Disorders; Olfactometry; Parkinson Disease; Prospective Studies; Psychophysics; Quality of Life; Severity of Illness Index

2013
Cardiac safety of rasagiline, a selective monoamine oxidase type B inhibitor for the treatment of Parkinson's disease: a thorough QT/QTc study.
    International journal of clinical pharmacology and therapeutics, 2014, Volume: 52, Issue:3

    Topics: Adolescent; Adult; Dose-Response Relationship, Drug; Double-Blind Method; Electrocardiography; Female; Heart Rate; Humans; Indans; Male; Middle Aged; Monoamine Oxidase Inhibitors; Parkinson Disease; Young Adult

2014
Symptomatic efficacy of rasagiline monotherapy in early Parkinson's disease: post-hoc analyses from the ADAGIO trial.
    Parkinsonism & related disorders, 2014, Volume: 20, Issue:6

    Topics: Cohort Studies; Double-Blind Method; Female; Humans; Indans; Male; Motor Activity; Neuroprotective Agents; Parkinson Disease

2014
Rasagiline effect on bladder disturbances in early mild Parkinson's disease patients.
    Parkinsonism & related disorders, 2014, Volume: 20, Issue:8

    Topics: Aged; Antiparkinson Agents; Female; Humans; Indans; Male; Middle Aged; Parkinson Disease; Urinary Bladder; Urodynamics

2014
Randomized, controlled trial of rasagiline as an add-on to dopamine agonists in Parkinson's disease.
    Movement disorders : official journal of the Movement Disorder Society, 2014, Volume: 29, Issue:8

    Topics: Aged; Dopamine Agonists; Double-Blind Method; Female; Humans; Indans; Male; Middle Aged; Neuroprotective Agents; Outcome Assessment, Health Care; Parkinson Disease; Severity of Illness Index; Time Factors; United States

2014
Intensive rehabilitation treatment in early Parkinson's disease: a randomized pilot study with a 2-year follow-up.
    Neurorehabilitation and neural repair, 2015, Volume: 29, Issue:2

    Topics: Aged; Analysis of Variance; Antiparkinson Agents; Disease Progression; Exercise Therapy; Female; Follow-Up Studies; Humans; Indans; Male; Parkinson Disease; Pilot Projects; Severity of Illness Index; Treatment Outcome; Walking

2015
Combined rasagiline and antidepressant use in Parkinson disease in the ADAGIO study: effects on nonmotor symptoms and tolerability.
    JAMA neurology, 2015, Volume: 72, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antidepressive Agents; Apathy; Depression; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Fatigue; Female; Humans; Indans; Male; Middle Aged; Neuroprotective Agents; Parkinson Disease; Psychiatric Status Rating Scales; Severity of Illness Index; Sleep; Treatment Outcome; Wakefulness

2015
Effects of rasagiline on the progression of nonmotor scores of the MDS-UPDRS.
    Movement disorders : official journal of the Movement Disorder Society, 2015, Volume: 30, Issue:4

    Topics: Activities of Daily Living; Disease Progression; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Humans; Indans; Male; Monoamine Oxidase Inhibitors; Parkinson Disease; Severity of Illness Index; Time Factors; Treatment Outcome

2015
The effects of rasagiline on cognitive deficits in Parkinson's disease patients without dementia: a randomized, double-blind, placebo-controlled, multicenter study.
    Movement disorders : official journal of the Movement Disorder Society, 2015, Volume: 30, Issue:7

    Topics: Cognition Disorders; Double-Blind Method; Humans; Indans; Neuroprotective Agents; Parkinson Disease

2015
A randomized clinical trial to evaluate the effects of rasagiline on depressive symptoms in non-demented Parkinson's disease patients.
    European journal of neurology, 2015, Volume: 22, Issue:8

    Topics: Aged; Depression; Double-Blind Method; Female; Humans; Indans; Male; Middle Aged; Neuroprotective Agents; Parkinson Disease; Treatment Outcome

2015
Pioglitazone in early Parkinson's disease: a phase 2, multicentre, double-blind, randomised trial.
    The Lancet. Neurology, 2015, Volume: 14, Issue:8

    Topics: Aged; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Indans; Male; Medical Futility; Middle Aged; Neuroprotective Agents; Parkinson Disease; Pioglitazone; Selegiline; Thiazolidinediones; Treatment Outcome

2015
Rasagiline for the symptomatic treatment of fatigue in Parkinson's disease.
    Movement disorders : official journal of the Movement Disorder Society, 2015, Volume: 30, Issue:13

    Topics: Adult; Aged; Aged, 80 and over; Double-Blind Method; Fatigue; Female; Follow-Up Studies; Humans; Indans; Male; Middle Aged; Neuroprotective Agents; Parkinson Disease; Pilot Projects; Severity of Illness Index; Statistics, Nonparametric; Treatment Outcome

2015
Rasagiline for mild cognitive impairment in Parkinson's disease: A placebo-controlled trial.
    Movement disorders : official journal of the Movement Disorder Society, 2016, Volume: 31, Issue:5

    Topics: Aged; Cognitive Dysfunction; Dopamine Agents; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Indans; Male; Middle Aged; Monoamine Oxidase Inhibitors; Outcome Assessment, Health Care; Parkinson Disease

2016
Effects of rasagiline on freezing of gait in Parkinson's disease - an open-label, multicenter study.
    Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia, 2016, Volume: 160, Issue:4

    Topics: Aged; Analysis of Variance; Antiparkinson Agents; Drug Administration Schedule; Female; Gait Disorders, Neurologic; Humans; Indans; Male; Parkinson Disease; Quality of Life; Surveys and Questionnaires; Treatment Outcome

2016
Dopamine D2 receptor gene variants and response to rasagiline in early Parkinson's disease: a pharmacogenetic study.
    Brain : a journal of neurology, 2016, Volume: 139, Issue:Pt 7

    Topics: Aged; Female; Follow-Up Studies; Humans; Indans; Male; Middle Aged; Monoamine Oxidase Inhibitors; Outcome Assessment, Health Care; Parkinson Disease; Pharmacogenomic Testing; Polymorphism, Single Nucleotide; Receptors, Dopamine D2; Severity of Illness Index; Tandem Repeat Sequences

2016
Cognitive Effects of Rasagiline in Mild-to-Moderate Stage Parkinson's Disease Without Dementia.
    The Journal of neuropsychiatry and clinical neurosciences, 2017,Winter, Volume: 29, Issue:1

    Topics: Aged; Aged, 80 and over; Analysis of Variance; Antiparkinson Agents; Cognition; Double-Blind Method; Female; Humans; Indans; Male; Middle Aged; Monoamine Oxidase Inhibitors; Neuropsychological Tests; Nootropic Agents; Parkinson Disease; Severity of Illness Index; Treatment Outcome

2017
Transtelephonic home blood pressure to assess the monoamine oxidase-B inhibitor rasagiline in Parkinson disease.
    Hypertension (Dallas, Tex. : 1979), 2008, Volume: 52, Issue:3

    Topics: Aged; Antihypertensive Agents; Antiparkinson Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Female; Food; Humans; Hypertension; Indans; Levodopa; Male; Middle Aged; Monoamine Oxidase Inhibitors; Parkinson Disease; Postprandial Period; Supine Position; Telephone; Tyramine

2008
A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): rationale, design, and baseline characteristics.
    Movement disorders : official journal of the Movement Disorder Society, 2008, Nov-15, Volume: 23, Issue:15

    Topics: Adult; Aged; Aged, 80 and over; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Indans; Male; Middle Aged; Neuroprotective Agents; Parkinson Disease; Retrospective Studies; Treatment Outcome

2008
Long-term outcome of early versus delayed rasagiline treatment in early Parkinson's disease.
    Movement disorders : official journal of the Movement Disorder Society, 2009, Mar-15, Volume: 24, Issue:4

    Topics: Adult; Aged; Antiparkinson Agents; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Humans; Indans; Levodopa; Longitudinal Studies; Male; Middle Aged; Monoamine Oxidase Inhibitors; Parkinson Disease; Quality of Life; Reproducibility of Results; Retrospective Studies; Severity of Illness Index; Time Factors; Treatment Outcome

2009
Validation of the freezing of gait questionnaire in patients with Parkinson's disease.
    Movement disorders : official journal of the Movement Disorder Society, 2009, Apr-15, Volume: 24, Issue:5

    Topics: Aged; Analysis of Variance; Antiparkinson Agents; Catechols; Double-Blind Method; Female; Freezing Reaction, Cataleptic; Gait Disorders, Neurologic; Humans; Indans; Levodopa; Male; Middle Aged; Neuroprotective Agents; Nitriles; Parkinson Disease; Principal Component Analysis; Psychiatric Status Rating Scales; Reproducibility of Results; Severity of Illness Index; Statistics as Topic; Surveys and Questionnaires

2009
A double-blind, delayed-start trial of rasagiline in Parkinson's disease.
    The New England journal of medicine, 2009, Sep-24, Volume: 361, Issue:13

    Topics: Adult; Aged; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Humans; Indans; Male; Middle Aged; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Parkinson Disease; Research Design; Severity of Illness Index

2009
Efficacy and tolerability of rasagiline in daily clinical use--a post-marketing observational study in patients with Parkinson's disease.
    European journal of neurology, 2010, Volume: 17, Issue:9

    Topics: Aged; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Indans; Male; Middle Aged; Neuroprotective Agents; Outcome Assessment, Health Care; Parkinson Disease; Patient Satisfaction; Quality of Life; Surveys and Questionnaires; Treatment Outcome

2010
Clinical pharmacology tyramine challenge study to determine the selectivity of the monoamine oxidase type B (MAO-B) inhibitor rasagiline.
    Journal of clinical pharmacology, 2010, Volume: 50, Issue:12

    Topics: Adult; Aged; Algorithms; Contraindications; Diet; Dose-Response Relationship, Drug; Double-Blind Method; Drug Labeling; Female; Humans; Hypertension; Indans; Isoenzymes; Male; Methoxyhydroxyphenylglycol; Middle Aged; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease; Selegiline; Tyramine; United States

2010
Long-term efficacy of rasagiline in early Parkinson's disease.
    The International journal of neuroscience, 2010, Volume: 120, Issue:6

    Topics: Antiparkinson Agents; Cohort Studies; Disease Progression; Dopamine Agents; Dopamine Agonists; Double-Blind Method; Drug Therapy, Combination; Follow-Up Studies; Humans; Indans; Kaplan-Meier Estimate; Levodopa; Middle Aged; Parkinson Disease; Severity of Illness Index; Time Factors; Treatment Outcome

2010
Determination of minimal clinically important change in early and advanced Parkinson's disease.
    Movement disorders : official journal of the Movement Disorder Society, 2011, Volume: 26, Issue:5

    Topics: Antiparkinson Agents; Disability Evaluation; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Humans; Indans; Levodopa; Male; Neuroprotective Agents; Parkinson Disease; Placebo Effect; ROC Curve; Severity of Illness Index; Time Factors; Treatment Outcome

2011
A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes.
    The Lancet. Neurology, 2011, Volume: 10, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Double-Blind Method; Female; Humans; Indans; Male; Middle Aged; Parkinson Disease; Severity of Illness Index; Time Factors; Treatment Outcome

2011
The effects of rasagiline on cognitive deficits in Parkinson's disease patients without dementia: a randomized, double-blind, placebo-controlled, multicenter study.
    Movement disorders : official journal of the Movement Disorder Society, 2011, Aug-15, Volume: 26, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Attention; Cognition Disorders; Dementia; Double-Blind Method; Executive Function; Female; Humans; Indans; Language; Male; Memory; Middle Aged; Neuroprotective Agents; Neuropsychological Tests; Parkinson Disease; Prospective Studies; Psychiatric Status Rating Scales; Visual Perception

2011
Efficacy, safety and tolerability of rasagiline as adjunctive therapy in elderly patients with Parkinson's disease.
    European journal of neurology, 2012, Volume: 19, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Indans; Male; Middle Aged; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Parkinson Disease; Treatment Outcome

2012
Effect of rasagiline as adjunct therapy to levodopa on severity of OFF in Parkinson's disease.
    European journal of neurology, 2011, Volume: 18, Issue:12

    Topics: Aged; Antiparkinson Agents; Catechols; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Dysarthria; Facial Expression; Female; Humans; Hypokinesia; Indans; Levodopa; Male; Middle Aged; Monoamine Oxidase Inhibitors; Motor Activity; Muscle Rigidity; Nitriles; Parkinson Disease; Severity of Illness Index; Tremor

2011
Rasagiline: time to onset of antiparkinson effect is similar when used as a monotherapy or adjunct treatment.
    The neurologist, 2011, Volume: 17, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Drug Therapy, Combination; Female; Humans; Hypokinesia; Indans; Male; Middle Aged; Monoamine Oxidase Inhibitors; Parkinson Disease; Prospective Studies; Time Factors

2011
Hyposmia in Parkinson's disease.
    Psychiatry and clinical neurosciences, 2012, Volume: 66, Issue:4

    Topics: Humans; Indans; Monoamine Oxidase Inhibitors; Olfaction Disorders; Parkinson Disease

2012
Evaluation of the safety and tolerability of rasagiline in the treatment of the early stages of Parkinson's disease.
    Current medical research and opinion, 2013, Volume: 29, Issue:1

    Topics: Aged; Antiparkinson Agents; Benzothiazoles; Double-Blind Method; Female; Gastrointestinal Diseases; Humans; Indans; Male; Middle Aged; Monoamine Oxidase Inhibitors; Parkinson Disease; Pramipexole; Sleep Wake Disorders; Time Factors

2013
Test-retest reliability of the unified Parkinson's disease rating scale in patients with early Parkinson's disease: results from a multicenter clinical trial.
    Movement disorders : official journal of the Movement Disorder Society, 2002, Volume: 17, Issue:4

    Topics: Activities of Daily Living; Aged; Antiparkinson Agents; Female; Humans; Indans; Male; Mental Status Schedule; Middle Aged; Motor Skills; Neurologic Examination; Observer Variation; Parkinson Disease; Reproducibility of Results

2002
A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study.
    Archives of neurology, 2002, Volume: 59, Issue:12

    Topics: Aged; Chi-Square Distribution; Double-Blind Method; Female; Humans; Indans; Logistic Models; Male; Middle Aged; Parkinson Disease

2002
A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease.
    Archives of neurology, 2004, Volume: 61, Issue:4

    Topics: Activities of Daily Living; Aged; Antiparkinson Agents; Cohort Studies; Disability Evaluation; Disease Progression; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Humans; Indans; Male; Middle Aged; Monoamine Oxidase Inhibitors; Parkinson Disease

2004
Double-blind, randomized, controlled trial of rasagiline as monotherapy in early Parkinson's disease patients.
    Movement disorders : official journal of the Movement Disorder Society, 2004, Volume: 19, Issue:8

    Topics: Adult; Aged; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Humans; Incidence; Indans; Male; Middle Aged; Monoamine Oxidase Inhibitors; Multicenter Studies as Topic; Parkinson Disease; Severity of Illness Index; Time Factors; Treatment Outcome

2004
A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study.
    Archives of neurology, 2005, Volume: 62, Issue:2

    Topics: Aged; Aged, 80 and over; Anorexia; Antiparkinson Agents; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Humans; Indans; Levodopa; Male; Middle Aged; Monoamine Oxidase Inhibitors; Motor Activity; Parkinson Disease; Retrospective Studies; Severity of Illness Index; Time Factors; Treatment Outcome; Vomiting; Weight Loss

2005
Rasagiline improves quality of life in patients with early Parkinson's disease.
    Movement disorders : official journal of the Movement Disorder Society, 2006, Volume: 21, Issue:5

    Topics: Aged; Analysis of Variance; Chi-Square Distribution; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Indans; Male; Middle Aged; Neuroprotective Agents; Neuropsychological Tests; Parkinson Disease; Quality of Life; Severity of Illness Index; Surveys and Questionnaires; Time Factors; Treatment Outcome

2006
Rasagiline-associated motor improvement in PD occurs without worsening of cognitive and behavioral symptoms.
    Journal of the neurological sciences, 2006, Oct-25, Volume: 248, Issue:1-2

    Topics: Aged; Behavioral Symptoms; Case-Control Studies; Cognition; Dopamine Agents; Double-Blind Method; Female; Humans; Indans; Levodopa; Male; Middle Aged; Monoamine Oxidase Inhibitors; Neuropsychological Tests; Parkinson Disease

2006
Effects of tyramine administration in Parkinson's disease patients treated with selective MAO-B inhibitor rasagiline.
    Movement disorders : official journal of the Movement Disorder Society, 2006, Volume: 21, Issue:10

    Topics: Administration, Oral; Aged; Antiparkinson Agents; Blood Pressure; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Food-Drug Interactions; Heart Rate; Humans; Indans; Levodopa; Male; Middle Aged; Monoamine Oxidase Inhibitors; Parkinson Disease; Risk Factors; Tyramine

2006

Other Studies

122 other study(ies) available for rasagiline and Idiopathic Parkinson Disease

ArticleYear
Reversible and irreversible small molecule inhibitors of monoamine oxidase B (MAO-B) investigated by biophysical techniques.
    Bioorganic & medicinal chemistry, 2015, Feb-15, Volume: 23, Issue:4

    Topics: Humans; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease; Small Molecule Libraries; Thermodynamics

2015
Novel arylalkenylpropargylamines as neuroprotective, potent, and selective monoamine oxidase B inhibitors for the treatment of Parkinson's disease.
    Journal of medicinal chemistry, 2015, Feb-12, Volume: 58, Issue:3

    Topics: Animals; Cell Survival; Cells, Cultured; Dose-Response Relationship, Drug; Humans; Mice; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Pargyline; Parkinson Disease; PC12 Cells; Propylamines; Rats; Structure-Activity Relationship

2015
Neuroprotective effects of benzyloxy substituted small molecule monoamine oxidase B inhibitors in Parkinson's disease.
    Bioorganic & medicinal chemistry, 2016, 11-15, Volume: 24, Issue:22

    Topics: Animals; Apoptosis; Cell Line; Cell Survival; Dose-Response Relationship, Drug; Mice; Mice, Inbred Strains; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Parkinson Disease; Rats; Small Molecule Libraries; Structure-Activity Relationship

2016
Discovery of coumarin Mannich base derivatives as multifunctional agents against monoamine oxidase B and neuroinflammation for the treatment of Parkinson's disease.
    European journal of medicinal chemistry, 2019, Jul-01, Volume: 173

    Topics: Animals; Coumarins; Dose-Response Relationship, Drug; Drug Discovery; Humans; Inflammation; Male; Mannich Bases; Mice; Mice, Inbred C57BL; Molecular Docking Simulation; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Parkinson Disease; Structure-Activity Relationship; Tumor Cells, Cultured

2019
Rasagiline derivatives combined with histamine H
    Bioorganic & medicinal chemistry letters, 2019, 10-01, Volume: 29, Issue:19

    Topics: Histamine H3 Antagonists; Humans; Indans; Monoamine Oxidase Inhibitors; Parkinson Disease; Receptors, Histamine H3

2019
Synthesis and human monoamine oxidase inhibitory activity of novel C2-, C3- and C4-substituted phthalonitriles.
    Bioorganic & medicinal chemistry letters, 2022, 10-15, Volume: 74

    Topics: Humans; Molecular Docking Simulation; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease; Structure-Activity Relationship

2022
The risk of melanoma with rasagiline compared with other antiparkinsonian medications: A retrospective cohort study in the United States medicare database.
    Pharmacoepidemiology and drug safety, 2022, Volume: 31, Issue:6

    Topics: Aged; Antiparkinson Agents; Cohort Studies; Female; Humans; Indans; Male; Medicare; Melanoma; Parkinson Disease; Retrospective Studies; Skin Neoplasms; United States

2022
Rasagiline, sleep quality and well-being in Parkinson's disease: a pilot study.
    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2022, Volume: 43, Issue:8

    Topics: Antiparkinson Agents; Humans; Indans; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Parkinson Disease; Pilot Projects; Quality of Life; Sleep Quality

2022
Effectiveness and safety of safinamide in routine clinical practice in a Belgian Parkinson's disease population: an open-label, levodopa add-on study.
    Acta neurologica Belgica, 2023, Volume: 123, Issue:3

    Topics: Aged; Antiparkinson Agents; Belgium; Drug-Related Side Effects and Adverse Reactions; Humans; Levodopa; Parkinson Disease; Prospective Studies; Retrospective Studies

2023
Effects of monotherapy with a monoamine oxidase B inhibitor on motor symptoms in Parkinson's disease are dependent on frontal function.
    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2023, Volume: 44, Issue:3

    Topics: Antiparkinson Agents; Dopamine; Dopamine Agents; Humans; Indans; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease; Selegiline

2023
Differences in CSF Biomarkers Profile of Patients with Parkinson's Disease Treated with MAO-B Inhibitors in Add-On.
    Journal of integrative neuroscience, 2022, Oct-08, Volume: 21, Issue:6

    Topics: Biomarkers; Humans; Lactates; Monoamine Oxidase Inhibitors; Parkinson Disease; Selegiline

2022
Safety and Effectiveness of Rasagiline in Chinese Patients with Parkinson's Disease: A Prospective, Multicenter, Non-interventional Post-marketing Study.
    Drug safety, 2023, Volume: 46, Issue:7

    Topics: Cohort Studies; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; East Asian People; Humans; Levodopa; Parkinson Disease; Prospective Studies; Treatment Outcome

2023
Effects of rasagiline combined with levodopa and benserazide hydrochloride on motor function and homocysteine and IGF-1 levels in elderly patients with Parkinson's disease.
    BMC neurology, 2023, Oct-06, Volume: 23, Issue:1

    Topics: Aged; Antiparkinson Agents; Benserazide; Homocysteine; Humans; Insulin-Like Growth Factor I; Levodopa; Middle Aged; Parkinson Disease

2023
Effectiveness and safety of safinamide in the Toledo Movement Disorders Unit.
    Revista de neurologia, 2023, 10-31, Volume: 77, Issue:S03

    Topics: Antiparkinson Agents; Humans; Levodopa; Parkinson Disease; Retrospective Studies

2023
Safety comparisons among monoamine oxidase inhibitors against Parkinson's disease using FDA adverse event reporting system.
    Scientific reports, 2023, 11-06, Volume: 13, Issue:1

    Topics: Amphetamines; Dopamine Agents; Humans; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease; Retrospective Studies; Selegiline

2023
Neuroprotective Effects of Rasagiline in Parkinson's Disease: A Regional Cerebral Blood Flow Study.
    Journal of neuroimaging : official journal of the American Society of Neuroimaging, 2019, Volume: 29, Issue:6

    Topics: Aged; Antiparkinson Agents; Cerebrovascular Circulation; Drug Therapy, Combination; Female; Humans; Indans; Levodopa; Male; Middle Aged; Neuroprotective Agents; Parkinson Disease; Tomography, Emission-Computed, Single-Photon; Treatment Outcome

2019
Identification of antiparkinsonian drugs in the 6-hydroxydopamine zebrafish model.
    Pharmacology, biochemistry, and behavior, 2020, Volume: 189

    Topics: Amantadine; Animals; Antiparkinson Agents; Behavior, Animal; Disease Models, Animal; Dopaminergic Neurons; Drug Repositioning; Indans; Isradipine; Larva; Levodopa; Locomotion; Motor Activity; Oxidopamine; Parkinson Disease; Phenotype; Zebrafish

2020
A new MAP-Rasagiline conjugate reduces α-synuclein inclusion formation in a cell model.
    Pharmacological reports : PR, 2020, Volume: 72, Issue:2

    Topics: alpha-Synuclein; Blood-Brain Barrier; Cell Culture Techniques; Cell Line, Tumor; Cell-Penetrating Peptides; Drug Carriers; Drug Design; Drug Evaluation, Preclinical; Humans; Indans; Neuroprotective Agents; Parkinson Disease; Protein Aggregation, Pathological; Solid-Phase Synthesis Techniques

2020
Ciprofloxacin-rasagiline drug interaction leading to dopaminergic effects.
    The Nurse practitioner, 2020, Volume: 45, Issue:5

    Topics: Aged; Ciprofloxacin; Dopamine Agents; Drug Interactions; Humans; Indans; Male; Nurse Practitioners; Parkinson Disease

2020
Serotonin syndrome in a Parkinson disease patient after intake of an ethanol-containing homeopathic medication.
    Neurodegenerative disease management, 2020, Volume: 10, Issue:4

    Topics: Aged; Citalopram; Drug Interactions; Ethanol; Female; Homeopathy; Humans; Indans; Parkinson Disease; Selective Serotonin Reuptake Inhibitors; Serotonin Syndrome

2020
Rasagiline monotherapy improves swallowing in patients with Parkinson's disease.
    Parkinsonism & related disorders, 2020, Volume: 78

    Topics: Aged; Aged, 80 and over; Deglutition Disorders; Female; Fluoroscopy; Humans; Indans; Male; Monoamine Oxidase Inhibitors; Parkinson Disease; Retrospective Studies; Treatment Outcome

2020
Overnight switch from rasagiline to safinamide in Parkinson's disease patients with motor fluctuations: a tolerability and safety study.
    European journal of neurology, 2021, Volume: 28, Issue:1

    Topics: Alanine; Antiparkinson Agents; Benzylamines; Drug Therapy, Combination; Humans; Indans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease

2021
Switch from rasagiline to safinamide in fluctuating Parkinson's disease patients: a retrospective, pilot study.
    Neurological research, 2021, Volume: 43, Issue:11

    Topics: Aged; Alanine; Antiparkinson Agents; Benzylamines; Drug Substitution; Female; Humans; Indans; Male; Middle Aged; Parkinson Disease; Pilot Projects; Retrospective Studies

2021
Efficacy of rasagiline and selegiline in Parkinson's disease: a head-to-head 3-year retrospective case-control study.
    Journal of neurology, 2017, Volume: 264, Issue:6

    Topics: Aged; Antiparkinson Agents; Case-Control Studies; Female; Follow-Up Studies; Humans; Indans; Italy; Male; Middle Aged; Parkinson Disease; Retrospective Studies; Selegiline; Severity of Illness Index

2017
Recurrent Impulse Control Disorder Associated with Rasagiline Treatment of Parkinson's Disease.
    The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques, 2017, Volume: 44, Issue:4

    Topics: Adult; Disruptive, Impulse Control, and Conduct Disorders; Humans; Indans; Male; Monoamine Oxidase Inhibitors; Parkinson Disease

2017
Rasagiline for dysexecutive symptoms during wearing-off in Parkinson's disease: a pilot study.
    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2018, Volume: 39, Issue:1

    Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Executive Function; Female; Humans; Indans; Levodopa; Male; Middle Aged; Monoamine Oxidase Inhibitors; Neuropsychological Tests; Parkinson Disease; Pilot Projects; Treatment Outcome

2018
Neuroprotective and Neuro-restorative Effects of Minocycline and Rasagiline in a Zebrafish 6-Hydroxydopamine Model of Parkinson's Disease.
    Neuroscience, 2017, Dec-26, Volume: 367

    Topics: Adrenergic Agents; Analysis of Variance; Animals; Disease Models, Animal; Dopaminergic Neurons; Drug Administration Schedule; Embryo, Nonmammalian; Indans; Isradipine; Levodopa; Locomotion; Minocycline; Neuroprotective Agents; Oxidopamine; Parkinson Disease; Time Factors; Tyrosine 3-Monooxygenase; Zebrafish

2017
Preparation and evaluation of injectable Rasagiline mesylate dual-controlled drug delivery system for the treatment of Parkinson's disease.
    Drug delivery, 2018, Volume: 25, Issue:1

    Topics: Animals; Delayed-Action Preparations; Drug Carriers; Drug Delivery Systems; Drug Liberation; Gels; Indans; Injections; Male; Mesylates; Microspheres; Oxidopamine; Parkinson Disease; Phase Transition; Rats; Rats, Sprague-Dawley

2018
α-Synuclein stimulation of monoamine oxidase-B and legumain protease mediates the pathology of Parkinson's disease.
    The EMBO journal, 2018, 06-15, Volume: 37, Issue:12

    Topics: alpha-Synuclein; Animals; Cysteine Endopeptidases; Disease Models, Animal; Dopamine; Indans; Mice; Mice, Transgenic; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease

2018
Safinamide effect on sleep disturbances and daytime sleepiness in motor fluctuating Parkinson's disease patients: A validated questionnaires-controlled study.
    Parkinsonism & related disorders, 2018, Volume: 57

    Topics: Aged; Alanine; Antiparkinson Agents; Benzylamines; Female; Humans; Indans; Male; Middle Aged; Parkinson Disease; Sleep; Sleep Wake Disorders; Surveys and Questionnaires

2018
Aldehyde adducts inhibit 3,4-dihydroxyphenylacetaldehyde-induced α-synuclein aggregation and toxicity: Implication for Parkinson neuroprotective therapy.
    European journal of pharmacology, 2019, Feb-15, Volume: 845

    Topics: 3,4-Dihydroxyphenylacetic Acid; Aldehydes; alpha-Synuclein; Animals; Indans; Neuroprotective Agents; Parkinson Disease; PC12 Cells; Rats

2019
Rasagiline and safinamide as a dopamine-sparing therapy for Parkinson's disease.
    Acta neurologica Scandinavica, 2019, Volume: 140, Issue:1

    Topics: Aged; Alanine; Antiparkinson Agents; Benzylamines; Drug Therapy, Combination; Female; Humans; Indans; Levodopa; Male; Middle Aged; Parkinson Disease

2019
Influence of DRD1 and DRD3 Polymorphisms in the Occurrence of Motor Effects in Patients with Sporadic Parkinson's Disease.
    Neuromolecular medicine, 2019, Volume: 21, Issue:3

    Topics: Antiparkinson Agents; Catechols; Cross-Sectional Studies; Dopamine; Dopamine Agonists; Genotype; Humans; Indans; Levodopa; Motor Activity; Nitriles; Parkinson Disease; Polymorphism, Single Nucleotide; Receptors, Dopamine D1; Receptors, Dopamine D3; Selegiline

2019
Three cases of impulse control disorder in Parkinson's disease patients receiving dopamine replacement therapy.
    Irish medical journal, 2013, Volume: 106, Issue:1

    Topics: Adult; Amantadine; Antiparkinson Agents; Benzothiazoles; Carbidopa; Catechols; Disruptive, Impulse Control, and Conduct Disorders; Drug Combinations; Female; Humans; Indans; Indoles; Levodopa; Male; Middle Aged; Neuroprotective Agents; Parkinson Disease; Pramipexole; Selegiline

2013
Encephalophaty associated with rasagiline and sertraline in Parkinson's disease: possible serotonin syndrome.
    Movement disorders : official journal of the Movement Disorder Society, 2013, Volume: 28, Issue:10

    Topics: Aged; Akathisia, Drug-Induced; Antiparkinson Agents; Brain Diseases; Delusions; Depressive Disorder, Major; Drug Interactions; Drug Therapy, Combination; Female; Humans; Indans; Myoclonus; Neuroprotective Agents; Parkinson Disease; Selective Serotonin Reuptake Inhibitors; Serotonin Syndrome; Sertraline

2013
Rasagiline ameliorates olfactory deficits in an alpha-synuclein mouse model of Parkinson's disease.
    PloS one, 2013, Volume: 8, Issue:4

    Topics: Age Factors; alpha-Synuclein; Animals; Disease Models, Animal; Humans; Indans; Memory, Short-Term; Mice; Mice, Transgenic; Monoamine Oxidase Inhibitors; Olfaction Disorders; Olfactory Bulb; Parkinson Disease; Smell

2013
Rapid onset of efficacy of rasagiline in early Parkinson's disease.
    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2013, Volume: 34, Issue:11

    Topics: Aged; Antiparkinson Agents; Female; Humans; Indans; Male; Monoamine Oxidase Inhibitors; Parkinson Disease; Single-Blind Method; Treatment Outcome

2013
Rasagiline in Parkinson's disease: the show must go on.
    Expert opinion on drug safety, 2013, Volume: 12, Issue:6

    Topics: Antiparkinson Agents; Humans; Indans; Monoamine Oxidase Inhibitors; Parkinson Disease

2013
[Livedo reticularis secondary to amantadine in a patient with Parkinson disease].
    Medicina clinica, 2014, Feb-20, Volume: 142, Issue:4

    Topics: Aged; Amantadine; Antiparkinson Agents; Carbidopa; Drug Therapy, Combination; Female; Humans; Indans; Levodopa; Livedo Reticularis; Parkinson Disease

2014
Rasagiline induced hypersexuality in Parkinson's disease.
    Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, 2014, Volume: 21, Issue:3

    Topics: Antiparkinson Agents; Disruptive, Impulse Control, and Conduct Disorders; Humans; Indans; Male; Middle Aged; Neuroprotective Agents; Parkinson Disease; Sexual Dysfunctions, Psychological

2014
Chronic monoamine oxidase-B inhibitor treatment blocks monoamine oxidase-A enzyme activity.
    Journal of neural transmission (Vienna, Austria : 1996), 2014, Volume: 121, Issue:4

    Topics: Aged; Aged, 80 and over; Dose-Response Relationship, Drug; Female; Humans; Indans; Male; Middle Aged; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease

2014
Apathy and associated factors in Mexican patients with Parkinson's disease.
    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2014, Volume: 35, Issue:5

    Topics: Age of Onset; Antiparkinson Agents; Apathy; Body Mass Index; Cross-Sectional Studies; Dopamine Agonists; Female; Humans; Indans; Male; Mexico; Middle Aged; Parkinson Disease; Prevalence; Psychiatric Status Rating Scales; Severity of Illness Index

2014
Insidious onset of Pisa syndrome after rasagiline therapy in a patient with Parkinson's disease.
    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2014, Volume: 35, Issue:10

    Topics: Aged; Antiparkinson Agents; Dystonia; Female; Humans; Indans; Parkinson Disease

2014
Brain targeted nanoparticulate drug delivery system of rasagiline via intranasal route.
    Drug delivery, 2016, Volume: 23, Issue:1

    Topics: Administration, Intranasal; Animals; Biological Availability; Brain; Chemistry, Pharmaceutical; Chitosan; Drug Compounding; Drug Delivery Systems; Goats; Indans; Male; Mice; Nanoparticles; Nasal Mucosa; Neuroprotective Agents; Parkinson Disease; Tissue Distribution

2016
A case of rasagiline-induced spontaneous orgasms in a female patient.
    Parkinsonism & related disorders, 2014, Volume: 20, Issue:8

    Topics: Adult; Antiparkinson Agents; Female; Humans; Indans; Orgasm; Parkinson Disease; Sexual Dysfunctions, Psychological

2014
Essential difference between the pharmacological spectrum of (-)-deprenyl and rasagiline.
    Pharmacological reports : PR, 2014, Volume: 66, Issue:3

    Topics: Animals; Indans; Learning Disabilities; Levodopa; Male; Neurons; Parkinson Disease; Rats; Rats, Wistar; Selegiline; Tetrabenazine

2014
Serotonin toxicity association with concomitant antidepressants and rasagiline treatment: retrospective study (STACCATO).
    Pharmacotherapy, 2014, Volume: 34, Issue:12

    Topics: Aged; Antidepressive Agents, Second-Generation; Cohort Studies; Drug Interactions; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Indans; Male; Middle Aged; Monoamine Oxidase Inhibitors; Parkinson Disease; Retrospective Studies; Selective Serotonin Reuptake Inhibitors; United States

2014
Early Parkinson's disease patients on rasagiline present with better odor discrimination.
    Journal of neural transmission (Vienna, Austria : 1996), 2015, Volume: 122, Issue:11

    Topics: Antiparkinson Agents; Cross-Sectional Studies; Discrimination, Psychological; Female; Humans; Indans; Levodopa; Male; Middle Aged; Neuroprotective Agents; Odorants; Olfaction Disorders; Olfactory Perception; Parkinson Disease; Physical Stimulation; Prospective Studies; Psychophysics; Sensory Thresholds; Severity of Illness Index; Treatment Outcome

2015
Severe dizziness following rivaroxaban introduction in a parkinsonian patient: Drug-drug interaction?
    Presse medicale (Paris, France : 1983), 2015, Volume: 44, Issue:11

    Topics: Anticoagulants; Antiparkinson Agents; Biotransformation; Dizziness; Drug Interactions; Drug Substitution; Drug Therapy, Combination; Factor Xa Inhibitors; Humans; Indans; Male; Middle Aged; Parkinson Disease; Rivaroxaban; Trihexyphenidyl; Venous Thrombosis; Warfarin

2015
Prescribing pattern and resource utilization of monoamine oxidase-B inhibitors in Parkinson treatment: comparison between rasagiline and selegiline.
    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2016, Volume: 37, Issue:2

    Topics: Aged; Antiparkinson Agents; Female; Health Care Costs; Hospitalization; Humans; Indans; Male; Middle Aged; Monoamine Oxidase Inhibitors; Parkinson Disease; Selegiline; Treatment Outcome

2016
BDNF levels are increased by aminoindan and rasagiline in a double lesion model of Parkinson׳s disease.
    Brain research, 2016, Jan-15, Volume: 1631

    Topics: Animals; Behavior, Animal; Benzylamines; Brain; Brain-Derived Neurotrophic Factor; Chaperonin 60; Cognition; Disease Models, Animal; Dopamine; Indans; Locomotion; Male; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neurons; Neuroprotective Agents; Norepinephrine; Parkinson Disease; Rats; Rats, Inbred F344

2016
Combination of Escitalopram and Rasagiline Induced Serotonin Syndrome: A Case Report and Review Literature.
    Journal of the Medical Association of Thailand = Chotmaihet thangphaet, 2015, Volume: 98, Issue:12

    Topics: Aged; Citalopram; Depression; Humans; Indans; Male; Parkinson Disease; Selective Serotonin Reuptake Inhibitors; Serotonin Syndrome; Treatment Outcome; Withholding Treatment

2015
Free-water and BOLD imaging changes in Parkinson's disease patients chronically treated with a MAO-B inhibitor.
    Human brain mapping, 2016, Volume: 37, Issue:8

    Topics: Aged; Brain Mapping; Cross-Sectional Studies; Female; Humans; Indans; Magnetic Resonance Imaging; Male; Middle Aged; Monoamine Oxidase Inhibitors; Parkinson Disease; Retrospective Studies; Substantia Nigra; Water

2016
[Problem solving care models for Parkinson's disease].
    Orvosi hetilap, 2016, May-29, Volume: 157, Issue:22

    Topics: Accidental Falls; Activities of Daily Living; Aged, 80 and over; Antiparkinson Agents; Cognitive Dysfunction; Constipation; Deglutition Disorders; Eating; Female; Hallucinations; Holistic Nursing; Humans; Indans; Neuroprotective Agents; Parkinson Disease; Patient Care Team; Pneumonia; Pressure Ulcer; Problem Solving; Psychomotor Agitation; Quality of Life; Skin Care; Sleep Initiation and Maintenance Disorders; Walking

2016
Parkinson disease: Dopamine receptor variants improve response to rasagiline in PD.
    Nature reviews. Neurology, 2016, Volume: 12, Issue:7

    Topics: Humans; Indans; Monoamine Oxidase Inhibitors; Parkinson Disease; Receptors, Dopamine D2

2016
Hypersexuality induced by rasagiline in monotherapy in Parkinson's disease.
    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2016, Volume: 37, Issue:11

    Topics: Aged; Humans; Indans; Male; Neuroprotective Agents; Parkinson Disease; Sexual Behavior

2016
Long-term effects of rasagiline and the natural history of treated Parkinson's disease.
    Movement disorders : official journal of the Movement Disorder Society, 2016, Volume: 31, Issue:10

    Topics: Aged; Female; Follow-Up Studies; Humans; Indans; Male; Middle Aged; Neuroprotective Agents; Outcome Assessment, Health Care; Parkinson Disease

2016
Patterns and predictors of freezing of gait improvement following rasagiline therapy: A pilot study.
    Clinical neurology and neurosurgery, 2016, Volume: 150

    Topics: Aged; Female; Gait Disorders, Neurologic; Humans; Indans; Male; Middle Aged; Monoamine Oxidase Inhibitors; Outcome Assessment, Health Care; Parkinson Disease; Pilot Projects

2016
Open-Label Study of Sleep Disturbances in Patients with Parkinson's Disease Treated with Rasagiline.
    The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques, 2016, Volume: 43, Issue:6

    Topics: Aged; Dose-Response Relationship, Drug; Female; Humans; Indans; Male; Middle Aged; Neuroprotective Agents; Parkinson Disease; Psychiatric Status Rating Scales; Retrospective Studies; Severity of Illness Index; Sleep Wake Disorders; Treatment Outcome

2016
Combination of paroxetine and rasagiline induces serotonin syndrome in a parkinsonian patient.
    Revue neurologique, 2016, Volume: 172, Issue:12

    Topics: Aged; Depressive Disorder, Major; Drug Interactions; Humans; Indans; Male; Monoamine Oxidase Inhibitors; Parkinson Disease; Paroxetine; Selective Serotonin Reuptake Inhibitors; Serotonin Syndrome

2016
Rasagiline-induced severe recurrent hypoglycemia in a young woman without diabetes: a case report.
    Journal of medical case reports, 2017, Feb-02, Volume: 11, Issue:1

    Topics: Adult; Female; Humans; Hypoglycemia; Indans; Monoamine Oxidase Inhibitors; Parkinson Disease

2017
Simultaneous determination of MAO-A and -B activity following first time intake of an irreversible MAO-B inhibitor in patients with Parkinson's disease.
    Journal of neural transmission (Vienna, Austria : 1996), 2017, Volume: 124, Issue:6

    Topics: Aged; Antiparkinson Agents; Female; Humans; Indans; Levodopa; Male; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease; Selegiline; Time Factors; Treatment Outcome

2017
[Rasagiline in daily clinical use. Results of a treatment study of Parkinson patients with a combination treatment].
    Fortschritte der Neurologie-Psychiatrie, 2008, Volume: 76, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Catechol O-Methyltransferase; Drug Therapy, Combination; Female; Humans; Indans; Levodopa; Male; Middle Aged; Neuroprotective Agents; Parkinson Disease; Quality of Life; Selegiline; Treatment Outcome

2008
Rasagiline ethanedisulfonate: an inhibitor for monoamine oxygenase B (MAO(B)).
    Acta crystallographica. Section C, Crystal structure communications, 2008, Volume: 64, Issue:Pt 11

    Topics: Crystallization; Crystallography, X-Ray; Hydrogen Bonding; Indans; Molecular Structure; Monoamine Oxidase Inhibitors; Parkinson Disease

2008
Selective MAO-B inhibitors have low potential for the tyramine effect.
    Movement disorders : official journal of the Movement Disorder Society, 2010, Jan-15, Volume: 25, Issue:1

    Topics: Blood Pressure; Heart Rate; Humans; Indans; Monoamine Oxidase Inhibitors; Parkinson Disease; Tyramine

2010
Drug selection and timing of initiation of treatment in early Parkinson's disease.
    Annals of neurology, 2008, Volume: 64 Suppl 2

    Topics: Aged; Aged, 80 and over; Animals; Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Dopamine Agonists; Humans; Indans; Levodopa; Middle Aged; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Parkinson Disease; Time Factors

2008
Genomic and proteomic study to survey the mechanism of action of the anti-Parkinson's disease drug, rasagiline compared with selegiline, in the rat midbrain.
    Journal of neural transmission (Vienna, Austria : 1996), 2009, Volume: 116, Issue:11

    Topics: Animals; Antiparkinson Agents; Biomarkers; Cell Survival; Female; Genomics; Indans; Nerve Growth Factors; Nerve Tissue Proteins; Neurogenesis; Neuroprotective Agents; Parkinson Disease; Proteomics; Rats; Rats, Wistar; Selegiline; Signal Transduction; Substantia Nigra

2009
Cost effectiveness of rasagiline and pramipexole as treatment strategies in early Parkinson's disease in the UK setting: an economic Markov model evaluation.
    Drugs & aging, 2009, Volume: 26, Issue:9

    Topics: Aged; Antiparkinson Agents; Benzothiazoles; Clinical Trials as Topic; Cost-Benefit Analysis; Disease Progression; Dopamine Agonists; Female; Health Care Costs; Humans; Indans; Insurance, Health, Reimbursement; Male; Markov Chains; Middle Aged; Models, Economic; Monoamine Oxidase Inhibitors; Monte Carlo Method; Parkinson Disease; Pramipexole; Probability; Quality-Adjusted Life Years; State Medicine; Treatment Outcome; United Kingdom

2009
Rasagiline-induced spontaneous ejaculation.
    Movement disorders : official journal of the Movement Disorder Society, 2009, Oct-30, Volume: 24, Issue:14

    Topics: Aged; Antiparkinson Agents; Ejaculation; Humans; Indans; Levodopa; Male; Monoamine Oxidase Inhibitors; Parkinson Disease; Sexual Behavior; Sexual Dysfunction, Physiological; Spinal Dysraphism

2009
Mao-B inhibitor know-how: back to the pharm.
    Neurology, 2009, Dec-08, Volume: 73, Issue:23

    Topics: Humans; Indans; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease; Substantia Nigra

2009
Rasagiline in Parkinson's disease.
    The New England journal of medicine, 2010, Feb-18, Volume: 362, Issue:7

    Topics: Animals; Dose-Response Relationship, Drug; Humans; Indans; Mice; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Parkinson Disease; Receptor Protein-Tyrosine Kinases

2010
Rasagiline in Parkinson's disease.
    The New England journal of medicine, 2010, Feb-18, Volume: 362, Issue:7

    Topics: Disease Progression; Dose-Response Relationship, Drug; Humans; Indans; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Outcome Assessment, Health Care; Parkinson Disease; Research Design

2010
Parkinson disease: ADAGIO trial hints that rasagiline slows disease progression.
    Nature reviews. Neurology, 2010, Volume: 6, Issue:3

    Topics: Clinical Trials as Topic; Disease Progression; Drug Delivery Systems; Humans; Indans; Neuroprotective Agents; Parkinson Disease; Time Factors

2010
The delayed-start study in Parkinson disease: can't satisfy everyone.
    Neurology, 2010, Apr-06, Volume: 74, Issue:14

    Topics: Data Interpretation, Statistical; Dose-Response Relationship, Drug; Endpoint Determination; Humans; Indans; Neuroprotective Agents; Outcome Assessment, Health Care; Parkinson Disease; Randomized Controlled Trials as Topic; Reproducibility of Results; Research Design; Risk Assessment; Time Factors; Treatment Outcome

2010
Reply to Drs. Olanow and Rascol.
    Neurology, 2010, Apr-06, Volume: 74, Issue:14

    Topics: Biomarkers; Clinical Trials as Topic; Data Interpretation, Statistical; Humans; Indans; Neuroprotective Agents; Outcome Assessment, Health Care; Parkinson Disease; Placebo Effect; Reproducibility of Results; Research Design

2010
Isolated delusional syndrome in Parkinson's Disease.
    Parkinsonism & related disorders, 2010, Volume: 16, Issue:8

    Topics: Aged; Amantadine; Antiparkinson Agents; Benserazide; Benzothiazoles; Catechols; Clonazepam; Female; Humans; Indans; Indoles; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Pramipexole; Schizophrenia, Paranoid; Syndrome

2010
Discordant effects of rasagiline doses in Parkinson disease.
    Nature reviews. Neurology, 2010, Volume: 6, Issue:7

    Topics: Dose-Response Relationship, Drug; Glyceraldehyde-3-Phosphate Dehydrogenases; Humans; Indans; Neuroprotective Agents; Parkinson Disease

2010
What is the clinical significance of the findings from the delayed-start trial of rasagiline in Parkinson's disease?
    Neuroepidemiology, 2010, Volume: 35, Issue:3

    Topics: Drug Administration Schedule; Humans; Indans; Neuroprotective Agents; Parkinson Disease; Randomized Controlled Trials as Topic; Research Design

2010
Delayed start, rapid solution?
    Neuroepidemiology, 2010, Volume: 35, Issue:3

    Topics: Alzheimer Disease; Drug Administration Schedule; Humans; Indans; Neuroprotective Agents; Parkinson Disease; Randomized Controlled Trials as Topic; Research Design

2010
Slowing the decline.
    Nature, 2010, Aug-26, Volume: 466, Issue:7310

    Topics: Antiparkinson Agents; Clinical Trials as Topic; Creatine; Humans; Indans; Parkinson Disease; Selegiline; Ubiquinone

2010
Treatment of advanced Parkinson's disease in the United States: a cost-utility model.
    Clinical drug investigation, 2010, Volume: 30, Issue:11

    Topics: Antiparkinson Agents; Carbidopa; Catechols; Cost Savings; Cost-Benefit Analysis; Disease Progression; Drug Administration Schedule; Drug Costs; Drug Therapy, Combination; Humans; Indans; Levodopa; Markov Chains; Models, Economic; Nitriles; Parkinson Disease; Quality of Life; Quality-Adjusted Life Years; Stochastic Processes; Time Factors; Treatment Outcome; United States

2010
[Rasagiline is not for all Parkinson disease patients: the ADAGIO study].
    Nederlands tijdschrift voor geneeskunde, 2010, Volume: 154

    Topics: Disease Progression; Dose-Response Relationship, Drug; Humans; Indans; Monoamine Oxidase Inhibitors; Parkinson Disease; Randomized Controlled Trials as Topic; Treatment Outcome

2010
The delayed-start study in Parkinson disease: can't satisfy everyone: Rasagiline, Parkinson neuroprotection, and delayed-start trials: still no satisfaction?
    Neurology, 2010, Nov-23, Volume: 75, Issue:21

    Topics: Clinical Trials as Topic; Drug Administration Schedule; Humans; Indans; Neuroprotective Agents; Parkinson Disease

2010
The delayed-start study in Parkinson disease: can't satisfy everyone: Rasagiline, Parkinson neuroprotection, and delayed-start trials: still no satisfaction?
    Neurology, 2010, Nov-23, Volume: 75, Issue:21

    Topics: Clinical Trials as Topic; Drug Administration Schedule; Humans; Indans; Neuroprotective Agents; Parkinson Disease

2010
Cost effectiveness of rasagiline and pramipexole as treatment strategies in early Parkinson's disease in the UK setting: An economic Markov model evaluation.
    Drugs & aging, 2011, Feb-01, Volume: 28, Issue:2

    Topics: Aged; Antiparkinson Agents; Benzothiazoles; Cost-Benefit Analysis; Dopamine Agonists; Humans; Indans; Markov Chains; Models, Economic; Monoamine Oxidase Inhibitors; Parkinson Disease; Pramipexole; United Kingdom

2011
MAO inhibitors.
    Cleveland Clinic journal of medicine, 2011, Volume: 78, Issue:2

    Topics: Depression; Humans; Indans; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease; Selegiline

2011
Rasagiline-induced serotonin syndrome.
    Movement disorders : official journal of the Movement Disorder Society, 2011, Volume: 26, Issue:4

    Topics: Aged; Female; Humans; Indans; Monoamine Oxidase Inhibitors; Parkinson Disease; Serotonin Syndrome

2011
[Efficacy of rasagiline in patients with advanced Parkinson's disease with motor fluctuation (azimut study)].
    Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2010, Volume: 110, Issue:11 Pt 2

    Topics: Aged; Female; Humans; Indans; Middle Aged; Monoamine Oxidase Inhibitors; Parkinson Disease; Treatment Outcome

2010
[Disease-modifying therapies in PD].
    Rinsho shinkeigaku = Clinical neurology, 2010, Volume: 50, Issue:11

    Topics: Animals; Disease Models, Animal; Disease Progression; Dopaminergic Neurons; Endpoint Determination; Humans; Indans; Parkinson Disease; Randomized Controlled Trials as Topic

2010
[The role of the MAO-B inhibitor razagiline in the treatment of Parkinson's disease].
    Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2011, Volume: 111, Issue:7

    Topics: Aged; Female; Humans; Indans; Male; Middle Aged; Monoamine Oxidase Inhibitors; Parkinson Disease; Speech Disorders; Treatment Outcome

2011
Reversible Pisa syndrome in patients with Parkinson's disease on rasagiline therapy.
    Movement disorders : official journal of the Movement Disorder Society, 2011, Volume: 26, Issue:14

    Topics: Aged; Dopamine Agents; Dyskinesia, Drug-Induced; Dystonia; Female; Humans; Indans; Male; Middle Aged; Neuroprotective Agents; Parkinson Disease

2011
Development of Parkinson's disease in patients with Narcolepsy.
    Journal of neural transmission (Vienna, Austria : 1996), 2012, Volume: 119, Issue:6

    Topics: Adult; Age of Onset; Antiparkinson Agents; Cataplexy; Central Nervous System Stimulants; Deep Brain Stimulation; Dextroamphetamine; Female; Humans; Hypokinesia; Indans; International Classification of Diseases; Levodopa; Male; Middle Aged; Narcolepsy; Neuroprotective Agents; Parkinson Disease; Sleep; Young Adult

2012
Livedo reticularis associated with rasagiline (azilect).
    Journal of drugs in dermatology : JDD, 2012, Volume: 11, Issue:6

    Topics: Aged; Female; Humans; Indans; Leg; Livedo Reticularis; Parkinson Disease

2012
Drugs for treating Parkinson disease.
    Nursing, 2012, Volume: 42, Issue:7

    Topics: Antiparkinson Agents; Apomorphine; Carbidopa; Catechols; Drug Combinations; Drugs, Generic; Humans; Indans; Levodopa; Nitriles; Parkinson Disease

2012
Rasagiline: a guide to its use in Parkinson's disease.
    CNS drugs, 2012, Sep-01, Volume: 26, Issue:9

    Topics: Administration, Oral; Antiparkinson Agents; Dopamine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Humans; Indans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Treatment Outcome

2012
Controlled release of rasagiline mesylate promotes neuroprotection in a rotenone-induced advanced model of Parkinson's disease.
    International journal of pharmaceutics, 2012, Nov-15, Volume: 438, Issue:1-2

    Topics: Animals; Apoptosis; Behavior, Animal; Cell Line, Tumor; Delayed-Action Preparations; Disease Models, Animal; Drug Carriers; Humans; Indans; Lactic Acid; Male; Microspheres; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Parkinson Disease; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Rats; Rats, Wistar; Rotenone

2012
[Medical therapy for Parkinson's disease--the current state of the art].
    Rinsho shinkeigaku = Clinical neurology, 2012, Volume: 52, Issue:11

    Topics: Humans; Indans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease

2012
Switch from selegiline to rasagiline is beneficial in patients with Parkinson's disease.
    Journal of neural transmission (Vienna, Austria : 1996), 2013, Volume: 120, Issue:5

    Topics: Aged; Amphetamine; Antiparkinson Agents; Drug Substitution; Female; Humans; Indans; Male; Methamphetamine; Middle Aged; Motor Activity; Neuroprotective Agents; Parkinson Disease; Selegiline; Severity of Illness Index; Time Factors

2013
Impulse control disorders induced by rasagiline as adjunctive therapy for Parkinson's disease: report of 2 cases.
    Parkinsonism & related disorders, 2013, Volume: 19, Issue:4

    Topics: Aged; Antiparkinson Agents; Disruptive, Impulse Control, and Conduct Disorders; Humans; Indans; Male; Middle Aged; Neuroprotective Agents; Parkinson Disease

2013
Monoamine oxidase inhibitors--is it time to up the TEMPO?
    The Lancet. Neurology, 2003, Volume: 2, Issue:3

    Topics: Antiparkinson Agents; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Indans; Levodopa; Monoamine Oxidase Inhibitors; Neurologic Examination; Parkinson Disease; Selegiline; Treatment Outcome

2003
Amyloid processing and signal transduction properties of antiparkinson-antialzheimer neuroprotective drugs rasagiline and TV3326.
    Annals of the New York Academy of Sciences, 2003, Volume: 993

    Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Carbamates; Cell Line; Enzyme Activation; Enzyme Inhibitors; Humans; Indans; Mitogen-Activated Protein Kinases; Neuroprotective Agents; Parkinson Disease; Rats; Signal Transduction

2003
Neuroprotection by monoamine oxidase B inhibitors: a therapeutic strategy for Parkinson's disease?
    BioEssays : news and reviews in molecular, cellular and developmental biology, 2004, Volume: 26, Issue:1

    Topics: Animals; Apoptosis; Enzyme Inhibitors; Humans; Indans; Models, Chemical; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neurons; Neurotoxins; Pargyline; Parkinson Disease; Propylamines; Time Factors

2004
Novel bifunctional drugs targeting monoamine oxidase inhibition and iron chelation as an approach to neuroprotection in Parkinson's disease and other neurodegenerative diseases.
    Journal of neural transmission (Vienna, Austria : 1996), 2004, Volume: 111, Issue:10-11

    Topics: Animals; Brain; Drug Delivery Systems; In Vitro Techniques; Indans; Iron Chelating Agents; Male; Mitochondria; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neurodegenerative Diseases; Neuroprotective Agents; Pargyline; Parkinson Disease; Piperazines; Propylamines; Quinolines; Rats; Rats, Sprague-Dawley

2004
[Rasagiline. A new monoamine oxidase b inhibitor for Parkinson treatment].
    Medizinische Monatsschrift fur Pharmazeuten, 2005, Volume: 28, Issue:7

    Topics: Animals; Antiparkinson Agents; Humans; Indans; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease

2005
Reexamination of the TEMPO Study.
    Archives of neurology, 2005, Volume: 62, Issue:8

    Topics: Antioxidants; Antiparkinson Agents; Artifacts; Drug Interactions; Humans; Indans; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Parkinson Disease; Patient Selection; Randomized Controlled Trials as Topic; Research Design; Selegiline; Treatment Outcome

2005
Rasagiline.
    Nature reviews. Drug discovery, 2005, Volume: 4, Issue:8

    Topics: Chemistry, Pharmaceutical; Clinical Trials as Topic; Drug Industry; Humans; Indans; Monoamine Oxidase Inhibitors; Parkinson Disease; Selegiline; Treatment Outcome

2005
[Rasagiline in motor fluctuations].
    Fortschritte der Neurologie-Psychiatrie, 2005, Volume: 73, Issue:9

    Topics: Drug Therapy, Combination; Humans; Indans; Monoamine Oxidase Inhibitors; Movement; Neuroprotective Agents; Parkinson Disease

2005
Rasagiline -- is there a place for this drug in managing Parkinson's disease?
    International journal of clinical practice, 2006, Volume: 60, Issue:2

    Topics: Humans; Indans; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Parkinson Disease

2006
[The early therapy challenge].
    Krankenpflege Journal, 2005, Volume: 43, Issue:7-10

    Topics: Antiparkinson Agents; Dopamine; Humans; Indans; Monoamine Oxidase Inhibitors; Neurons; Neuroprotective Agents; Parkinson Disease; Randomized Controlled Trials as Topic

2005
Cost-utility model of rasagiline in the treatment of advanced Parkinson's disease in Finland.
    The Annals of pharmacotherapy, 2006, Volume: 40, Issue:4

    Topics: Antiparkinson Agents; Cost-Benefit Analysis; Drug Costs; Drug Therapy, Combination; Drug Utilization; Finland; Humans; Indans; Levodopa; Markov Chains; Models, Statistical; Parkinson Disease; Treatment Outcome

2006
Safety of rasagiline in elderly patients with Parkinson disease.
    Neurology, 2006, May-09, Volume: 66, Issue:9

    Topics: Age Factors; Aged; Aged, 80 and over; Antiparkinson Agents; Confusion; Disorders of Excessive Somnolence; Dopamine Agonists; Double-Blind Method; Female; Hallucinations; Humans; Hypotension, Orthostatic; Incidence; Indans; Levodopa; Male; Middle Aged; Monoamine Oxidase Inhibitors; Parkinson Disease; Randomized Controlled Trials as Topic

2006
Clinical trials with rasagiline: evidence for short-term and long-term effects.
    Neurology, 2006, May-23, Volume: 66, Issue:10 Suppl 4

    Topics: Evidence-Based Medicine; Humans; Indans; Neuroprotective Agents; Parkinson Disease; Practice Guidelines as Topic; Practice Patterns, Physicians'; Randomized Controlled Trials as Topic; Treatment Outcome

2006
Rationale for considering that propargylamines might be neuroprotective in Parkinson's disease.
    Neurology, 2006, May-23, Volume: 66, Issue:10 Suppl 4

    Topics: Clinical Trials as Topic; Evidence-Based Medicine; Humans; Indans; Neuroprotective Agents; Pargyline; Parkinson Disease; Practice Guidelines as Topic; Practice Patterns, Physicians'; Propylamines; Selegiline; Treatment Outcome

2006
Rasagiline as a therapy for Parkinson's disease (PD).
    The American journal of geriatric pharmacotherapy, 2007, Volume: 5, Issue:2

    Topics: Drug Interactions; Humans; Indans; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Parkinson Disease; Selegiline

2007
Neuroprotection by propargylamines in Parkinson's disease: intracellular mechanism underlying the anti-apoptotic function and search for clinical markers.
    Journal of neural transmission. Supplementum, 2007, Issue:72

    Topics: Alkynes; Cell Death; Cell Line, Tumor; Energy Metabolism; Genetic Markers; Glial Cell Line-Derived Neurotrophic Factor; Humans; Indans; Membrane Potentials; Mitochondria; Neuroblastoma; Neuroprotective Agents; NF-kappa B; Oligonucleotide Array Sequence Analysis; Pargyline; Parkinson Disease; Propylamines; Proto-Oncogene Proteins c-bcl-2; Selegiline

2007
Influence of selective inhibition of monoamine oxidase A or B on striatal metabolism of L-DOPA in hemiparkinsonian rats.
    Journal of neurochemistry, 1995, Volume: 65, Issue:3

    Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Clorgyline; Corpus Striatum; Dialysis; Dopamine; Homovanillic Acid; Indans; Levodopa; Male; Monoamine Oxidase Inhibitors; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Selegiline; Substantia Nigra

1995
Neuroprotection by (-)-deprenyl and related compounds.
    Mechanisms of ageing and development, 1999, Volume: 111, Issue:2-3

    Topics: Aging; Amphetamines; Animals; Antioxidants; Apoptosis; Cattle; DNA Damage; DNA, Neoplasm; Indans; Monoamine Oxidase Inhibitors; Neuroblastoma; Neuroprotective Agents; Nitrates; Oxidants; Parkinson Disease; Selegiline; Tumor Cells, Cultured

1999
The neuronal survival effects of rasagiline and deprenyl on fetal human and rat ventral mesencephalic neurones in culture.
    Neuroreport, 2000, Dec-18, Volume: 11, Issue:18

    Topics: Animals; Cell Survival; Cells, Cultured; Female; Fetus; Humans; Indans; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neurons; Neuroprotective Agents; Parkinson Disease; Pregnancy; Rats; Rats, Sprague-Dawley; Selegiline; Substantia Nigra

2000
Transfection-enforced Bcl-2 overexpression and an anti-Parkinson drug, rasagiline, prevent nuclear accumulation of glyceraldehyde-3-phosphate dehydrogenase induced by an endogenous dopaminergic neurotoxin, N-methyl(R)salsolinol.
    Journal of neurochemistry, 2001, Volume: 78, Issue:4

    Topics: Active Transport, Cell Nucleus; Animals; Apoptosis; Cell Line; Cell Nucleus; Glyceraldehyde-3-Phosphate Dehydrogenases; Humans; Immunoblotting; Immunohistochemistry; Indans; Membrane Potentials; Mitochondria; Neuroprotective Agents; Neurotoxins; Parkinson Disease; Proto-Oncogene Proteins c-bcl-2; Salsoline Alkaloids; Signal Transduction; Tetrahydroisoquinolines; Transfection

2001
Rasagiline. Teva Pharmaceutical.
    Current opinion in investigational drugs (London, England : 2000), 2002, Volume: 3, Issue:5

    Topics: Administration, Oral; Alzheimer Disease; Animals; Clinical Trials as Topic; Humans; Indans; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Parkinson Disease; Structure-Activity Relationship

2002
Monoamine oxidase activity and monoamine metabolism in brains of parkinsonian patients treated with l-deprenyl.
    Journal of neurochemistry, 1986, Volume: 46, Issue:5

    Topics: Aged; Amines; Brain; Dopamine; Female; Humans; Hydroxyindoleacetic Acid; Indans; Kynuramine; Male; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease; Phenethylamines; Selegiline; Serotonin; Tissue Distribution; Tranylcypromine

1986
MAO type B inhibitors as adjunct to L-dopa therapy.
    Advances in neurology, 1987, Volume: 45

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Alkynes; Animals; Brain; Drug Therapy, Combination; Humans; Indans; Isoenzymes; Levodopa; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Pargyline; Parkinson Disease; Parkinson Disease, Secondary; Pyridines; Receptors, Dopamine; Selegiline; Structure-Activity Relationship; Tyramine

1987